Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesVascular/Cardiothoracic Surgeryevicore PVI carotid and arterial Coverage Update |…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentevicorePolicy PVI.100.A

    Peripheral Vascular Intervention (PVI) — carotid and arterial revascularization guidance

    Customize your policy alerts

    Sign up for evicore Policy PVI.100.A alerts

    Get alerted when Policy PVI.100.A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage policy governing prior-authorization, documentation, and medical necessity determinations for peripheral vascular interventions (including carotid and vertebral revascularization) for Cigna-administered plans; applies to providers requesting authorization for vascular/endovascular procedures.

    Policy Summary
    Payerevicore
    PolicyPeripheral Vascular Intervention (PVI) — carotid and arterial revascularization guidance
    Policy CodePolicy PVI.100.A
    Change TypeNo material change
    Effective DateNov 5, 2026
    Next Review Date
    Key ActionSubmit prior-authorization at least two weeks before elective procedures with recent diagnostic imaging (within 6 months) and documentation of conservative therapy and clinical findings to support medical necessity.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    98document pages
    6 monthsrecency window
    50%high-grade stenosis threshold
    ≥50%
    symptomatic CEA threshold
    ≥70%asymptomatic CEA threshold

    Coverage Criteria and Medical Necessity

    Carotid and Vertebral Revascularization — medical necessity considerations

    Determination is case-by-case based on clinical presentation, imaging, and urgency; urgent/emergent indications allow definitive surgical or endovascular treatment without preceding non-surgical management.

    Urgent/emergent indications: If ANY of the following are present: crescendo TIAs; transient monocular blindness (amaurosis fugax); free-floating thrombus; enlarging carotid pseudoaneurysm; infection of prior carotid patch; recent CVA or TIA; or symptomatic carotid stenosis — definitive surgical or endovascular treatment is warranted without required non-surgical management.

    Confirmatory imaging and clinical notes are required.

    Procedure inclusion: Accepted procedures include carotid endarterectomy (CEA), transfemoral carotid artery stenting (TFCAS/CAS), and transcarotid artery revascularization (TCAR).
    Not medically necessary condition: Carotid revascularization (CEA or CAS) is not medically necessary for individuals who have had a disabling stroke.modified Rankin >=3

    Asymptomatic individuals should have adequate life expectancy to benefit.

    Symptomatic carotid stenosis - CEA

    Covered when ALL of the following are met

    Symptomatic CEA: Carotid endarterectomy (CEA) is medically necessary when: 1) Carotid stenosis ≥50% documented by angiogram, CTA, carotid duplex, or MRA; AND 2) Presence of transient ischemic attack (TIA), focal cerebral ischemia producing a non-disabling stroke, or transient monocular blindness (amaurosis fugax) anatomically corresponding to the lesion.stenosis >=50%

    Asymptomatic carotid stenosis - CEA

    Covered when ALL of the following are met

    Asymptomatic CEA: Carotid endarterectomy (CEA) is medically necessary for asymptomatic carotid stenosis when stenosis is ≥70% by NASCET criteria on carotid duplex, CTA, MRA, or angiogram performed within the last 6 months and documented in clinical notes.stenosis >=70% (NASCET) within 6 months

    CAS/TCAR when high-risk for CEA

    CAS or TCAR is considered medically necessary when ALL of the following are met

    CAS/TCAR when CEA criteria met and high-risk for CEA: Individual meets criteria for carotid revascularization AND is high-risk for CEA due to documented comorbidities or anatomic risk factors such as CHF class III/IV; LVEF <30%; unstable angina or recent MI; severe COPD; ESRD; age ≥75; prior neck radiation or radical neck dissection; permanent contralateral cranial nerve injury; contralateral carotid occlusion; tandem high-grade ipsilateral stenosis; high cervical stenosis above C2; Takayasu arteritis with stenosis; carotid pseudoaneurysm; carotid dissection with stenosis; or fibromuscular dysplasia with stenosis.

    Specific high-risk conditions must be documented in clinical record.

    Recurrent carotid stent restenosis

    Intervention for recurrent stenosis after prior carotid stent is medically necessary when ANY of the following sets of conditions are met

    Recurrent symptomatic restenosis: Symptomatic recurrent stenosis with either duplex peak systolic velocity (PSV) ≥240 cm/sec OR CTA/MRA/angiogram evidence of ≥50% stenosis.PSV >=240 cm/sec or imaging >=50%
    Recurrent asymptomatic restenosis: Asymptomatic recurrent stenosis with either duplex PSV ≥370 cm/sec OR CTA/MRA/angiogram evidence of ≥70% stenosis.PSV >=370 cm/sec or imaging >=70%

    Extracranial vertebral artery stenosis - stenting

    Extracranial vertebral artery angioplasty with stent placement is considered medically necessary when ALL of the following are met

    Vertebral artery stenting: Failure of antiplatelet or anticoagulation therapy; non-vascular etiologies excluded or treated; clinical history documents ongoing posterior circulation symptoms (eg, dizziness, unilateral limb weakness, dysarthria, recurrent headache, recurrent nausea/vomiting, or recurrent posterior circulation embolic stroke); AND one of: 60–99% bilateral extracranial vertebral artery stenosis OR 60–99% unilateral extracranial vertebral artery stenosis with a dominant vertebral and hypoplastic contralateral artery OR contralateral vertebral artery ending in PICA OR contralateral vertebral artery occluded.stenosis 60-99%

    Endovascular iliac branched endograft (CPT 34717)

    Medically necessary when clinical history documents ALL of the following:

    CPT 34717 medical necessity criteria: 1) Endovascular abdominal aortic aneurysm (AAA) repair is planned at the same time as the internal iliac artery (IIA) procedure; 2) Ipsilateral common iliac artery aneurysm >3.5 cm diameter; 3) Contralateral internal iliac artery occlusion.

    All three conditions must be documented.

    Endovascular repair of isolated internal iliac artery aneurysm

    Endovascular intervention (stenting, embolization, or embolization plus stenting) is medically necessary for ANY of the following:

    Internal iliac aneurysm intervention indications: Symptomatic internal iliac aneurysm of any size; OR asymptomatic internal iliac aneurysm measuring ≥3.0 cm; OR evidence of bleeding from the aneurysm such as active extravasation or adjacent hematoma.

    Any one of these supports medical necessity.

    Bifurcated-bifurcated aneurysm repair (CPT 34718)

    CPT 34718 stance: Bifurcated-bifurcated aneurysm repair (CPT 34718) for aorto-iliac aneurysms is considered experimental, investigational, and unproven; effectiveness has not been established.

    This approach is not supported by the guideline.

    Popliteal artery aneurysm — Indications for endovascular repair

    Endovascular repair of popliteal artery aneurysms is considered medically necessary when the following criteria are met:

    Popliteal aneurysm criteria: Either: asymptomatic popliteal artery aneurysm with diameter ≥2.0 cm on US, CT, or MRI; OR symptomatic popliteal artery aneurysm with diameter ≥1.5 cm on US, CT, or MRI AND both mural thrombus within the aneurysm AND evidence of new onset claudication, critical limb-threatening ischemia, or blue toe syndrome.see node text

    Symptomatic pathway requires both mural thrombus and ischemic symptoms.

    Visceral artery aneurysm/pseudoaneurysm — Indications for coil embolization

    Coil embolization is medically necessary when diagnostic imaging documents any of the following vessel- and size-specific conditions:

    Visceral aneurysm/PSA size-vessel criteria: Hepatic artery aneurysm ≥2.0 cm; celiac artery aneurysm ≥2.0 cm (and any size celiac PSA); colic artery aneurysm any size; gastric and gastroepiploic aneurysm any size; jejunal/ileal artery aneurysm ≥2.0 cm; superior mesenteric artery (SMA) aneurysm any size; pancreaticoduodenal and gastroduodenal aneurysm any size; splenic artery aneurysm ≥3.0 cm OR splenic aneurysm of any size in individuals with child-bearing potential; any size splenic artery pseudoaneurysm; renal artery aneurysm ≥3.0 cm.see node text

    Imaging modality must be CTA, MRA, US, or angiogram.

    Brachiocephalic artery indications

    PTA and stenting medically necessary when documented conditions are present

    Indications for brachiocephalic PTA/stent: Any of the following documented conditions: symptomatic subclavian steal syndrome with episodic dizziness plus high-grade proximal subclavian stenosis on advanced imaging and reversal of vertebral flow on duplex; upper extremity claudication with reproducible exertional fatigue relieved by rest; ischemic rest pain or non-healing tissue ulceration/gangrene of the arm/hand with objective severe ischemia or high-grade stenosis on imaging; or stenotic inflow arteries of an AV fistula with high-grade stenosis on imaging.

    Each listed condition is sufficient if documented.

    Initial treatment for claudication (aorto-iliac, superficial femoral, popliteal)

    Covered when ALL of the following are met:

    Claudiation initial therapy criteria: Treatment is medically necessary when: 1) Intervention will restore in-line flow to the foot with at least one run-off vessel; 2) Lifestyle-limiting claudication with failed trial of 3 months of provider-directed conservative therapy (including structured exercise if available) with documented follow-up; 3) Functional limitations significantly impacting quality of life/occupation; 4) Risk-factor modification addressed (smoking cessation, lipid and glycemic optimization); 5) Symptoms correspond to lesion location; AND 6) Imaging confirms lesion location and degree of stenosis ≥50% by objective criteria.all required; stenosis >=50%

    Supports angioplasty/stent/atherectomy decision making.

    Repeat intervention for recurrent claudication

    Covered when ANY one of the following surveillance or imaging findings is present after prior endovascular intervention or bypass:

    Post-endovascular triggers: Drop in ABI ≥0.15 on routine surveillance; OR duplex PSV ≥190 cm/s; OR velocity ratio ≥1.5; OR ≥50% stenosis on CTA/MRA/angiogram following prior endovascular intervention.any one triggers coverage

    Applies to previous endovascular intervention.

    Post-bypass triggers: Drop in ABI ≥0.15; OR vein bypass PSV ≥180 cm/s; OR velocity ratio ≥2; OR end diastolic velocity <45 cm/s; OR ≥50% stenosis on CTA/MRA/angiogram following prior bypass.any one triggers coverage

    Applies to previous lower extremity bypass.

    Asymptomatic high-grade restenosis after intervention: In asymptomatic individuals, high-grade restenosis criteria include PSV ≥275 cm/s or velocity ratio ≥3.5 after prior endovascular intervention; or PSV ≥180 cm/s, velocity ratio ≥2, EDV <45 cm/s, or low graft velocity <45 cm/s after prior bypass.

    Atherectomy for claudication

    Covered when ALL of the following are met:

    Atherectomy criteria: Criteria for intervention per Initial Treatment or Repeat Intervention are met; AND the lesion results in ≥70% stenosis caused by highly calcified eccentric plaque.stenosis >=70%

    Repeat atherectomy for recurrent infrapopliteal stenosis/occlusion without evidence of critical limb ischemia is not considered medically necessary.

    Initial treatment for critical limb ischemia (CLI)

    Covered when ALL of the following are met:

    CLI documentation: Clinical documentation of critical limb ischemia by any of: non-healing ischemic/mixed wounds >2 weeks despite wound care; gangrene when revascularization is needed to allow minor amputation; ischemic rest pain with ABI <0.5 (non-diabetics) or TBI <0.6 or monophasic waveforms at feet in diabetics/ESRD; documented infrapopliteal disease ≥50% stenosis; imaging confirming ≥50% stenosis by objective criteria; AND symptoms correspond with arterial insufficiency location.all required; stenosis >=50%

    Supports endovascular intervention in CLI.

    Inframalleolar angioplasty

    Covered when ALL of the following are met:

    Inframalleolar criteria: Individual has active tissue loss in the foot and lack of arterial flow distal to the ankle (GLASS P2); imaging demonstrates occluded distal ATA/DP or occluded PTA/Tarsal branches at the ankle on CTA/MRA/angiogram or duplex shows lack of flow; AND pedal acceleration time (PAT) >225 ms.PAT >225 ms

    Limited to individuals with active tissue loss.

    Atherectomy and intravascular lithotripsy for CLI

    Covered when ALL of the following are met:

    Atherectomy for CLI: Clinical history documents CLI (tissue loss or ischemic rest pain) and the individual otherwise satisfies Initial Intervention or Repeat Intervention criteria.all required

    Atherectomy permitted in CLI when standard criteria met.

    IVL for CLI: Clinical history documents CLI (tissue loss or ischemic rest pain), the individual otherwise satisfies Initial Intervention or Repeat Intervention criteria, AND there is evidence of ≥50% stenosis or occlusion due to moderate or severely calcified plaque in the iliac or femoral-popliteal vessels on duplex, CTA, MRA or prior angiogram.stenosis >=50% with calcified plaque

    IVL coverage tied to calcified lesion evidence.

    Endovenous ablation — medical necessity

    Treatment of saphenovenous reflux is medically necessary when ALL of the following are met:

    Saphenous vein treatment criteria: 1) Symptoms attributable to incompetent veins (not cosmetic) AND CEAP classification ≥ C2 or VCSS ≥6; 2) Venous duplex within 6 months demonstrating significant pathologic truncal vein reflux ≥500 ms in required segments (≥2 segments for GSV above-knee or SSV; ≥1 segment for ASV, PASV, or GSV below-knee); 3) Absence of ipsilateral acute lower extremity DVT or chronic multisegmental femoral-popliteal occlusion.reflux >=500 ms; duplex within 6 months

    Maintain segment-specific requirements as stated.

    Treatment limitations

    When medical necessity criteria for saphenous vein treatment are met, the following limitations apply:

    Treatment limitations: Maximum of 2 truncal veins per extremity per treatment session is medically necessary; additional truncal vein treatment in the same extremity is medically necessary only ≥12 weeks after initial treatment if symptoms fail to improve; limitations do not apply in the setting of an active ulcer.<=2 truncal veins per session; >=12 weeks interval

    Exceptions for active ulcers.

    Modality and sequencing

    Saphenous vein treatment using different modalities may be considered when specific conditions are met:

    Modality sequencing rules: Small saphenous vein may be treated with one modality in a single episode; thigh extension (Giacomini) may be treated same episode or ≥12 weeks later; greater saphenous vein above- and below-knee may be treated with a single modality in one episode or with two different modalities concurrently; subsequent below-knee different-modality treatment may be considered ≥12 weeks if symptoms persist; repeat treatment of same segment is not supported.12 weeks for staged changes

    Detailed sequencing preserved.

    Perforator veins — medical necessity

    Treatment of pathologic perforator veins is medically necessary when ALL of the following are documented:

    Perforator treatment: Active venous stasis ulcer; recent venous duplex within 6 months demonstrating perforator reflux ≥500 ms AND perforator diameter ≥3.5 mm; perforator located in the vicinity of the active ulcer; AND saphenous veins draining the ulcer area have been previously eliminated or do not exhibit pathologic reflux.reflux >=500 ms and diameter >=3.5 mm

    Requires proximity to active ulcer and prior saphenous treatment or absence of saphenous reflux.

    Inframalleolar/pedal artery interventions

    Inframalleolar and pedal arterial interventions coverage stance:

    Inframalleolar/pedal intervention: Intervention on inframalleolar/pedal arteries is limited to individuals with active ulcers or tissue loss and is not indicated for patients with rest pain or claudication due to lack of durable proven outcomes.N/A

    Requires imaging showing occluded distal target vessels or GLASS P2 descriptors where applicable.

    Renal artery intervention criteria

    Renal artery intervention is medically necessary when the following apply:

    Renal/visceral intervention indications: Failure of medical therapy to control hypertension with duplex or CT/MR imaging confirming renal artery stenosis; OR selected scenarios such as fibromuscular dysplasia, renal artery dissection, acute renal failure due to flow-limiting lesion, or transplant renal artery stenosis considered case-by-case. Intervention is not indicated without uncontrolled hypertension and is not recommended in advanced renal disease or chronic renal artery occlusion.N/A

    Primary stenting is medically necessary when PTA alone unlikely to be durable for high-risk occlusions, ostial or heavily calcified lesions.

    Non-compounded foam sclerotherapy - Medical necessity

    Treatment of saphenovenous reflux by non-compounded microfoam is considered medically necessary when ALL of the following are met:

    Non-compounded foam sclerotherapy primary criteria: Symptomatic reflux with CEAP ≥ C2 or VCSS ≥6; venous duplex within 6 months demonstrating significant pathologic truncal vein reflux ≥500 ms in required segments; absence of ipsilateral acute DVT or chronic multisegmental femoral-popliteal occlusion.duplex within 6 months; reflux >=500 ms

    Varithena is manufacturer-limited to ≤15 mL/session; physician-compounded foam not shown to be less safe or effective for varicose veins/tributaries.

    Perforator vein treatment - Medical necessity

    Treatment of pathologic perforators is considered medically necessary when ALL of the following are documented:

    Perforator criteria (ulcer): Active venous stasis ulcer AND recent duplex within 6 months showing perforator reflux ≥500 ms AND perforator diameter ≥3.5 mm AND perforator located in vicinity of the active ulcer AND saphenous veins draining the ulcer have been eliminated or do not exhibit pathologic reflux.reflux >=500 ms; diameter >=3.5 mm

    Perforator treatment only indicated for active venous stasis ulcer; saphenous reflux should be addressed first.

    Treatment limitations and sequencing

    Limits and sequencing applicable when medical necessity criteria are met:

    Session limits and sequencing: Maximum of 2 truncal veins per extremity per treatment session is medically necessary; additional truncal vein treatment in same extremity is medically necessary only ≥12 weeks after initial treatment if symptoms persist; limitations do not apply in the presence of an active ulcer. Above- and below-knee segments may be treated with same or different modalities per detailed rules; repeat treatment of same segment is not supported without recurrent reflux or symptoms.2 veins per session; >=12 weeks interval

    Detailed modality sequencing rules apply.

    High Ligation and Stripping — Medical Necessity

    Considered medically necessary when ALL of the following are met

    High ligation/stripping criteria: Symptomatic reflux with CEAP C2+ or VCSS ≥6; venous duplex within 6 months demonstrating significant pathologic truncal vein reflux ≥500 ms per vein/segment rules; absence of ipsilateral acute DVT or chronic multisegmental femoral-popliteal occlusion.reflux >=500 ms

    Maximum 2 truncal veins per extremity per session; additional truncal treatment ≥12 weeks after initial unless active ulcer; limitations not applicable for active ulcer.

    Phlebectomy of Saphenovenous Tributaries — Medical Necessity

    Medically necessary when ALL of the following are met

    Phlebectomy criteria: Symptomatic reflux with CEAP C2+ or VCSS ≥6; recent venous duplex or objective measurement within 6 months demonstrating tributaries ≥6 mm or ≥3 mm with ≥500 ms reflux; documentation of either failed symptoms after 12 weeks observation following prior endovenous ablation (except venous ulcer cases), OR tributaries to be treated concurrently with saphenous ablation, OR existing saphenous veins do not exhibit pathologic reflux.>=6 mm OR >=3 mm with >=500 ms reflux

    Observation period does not apply to venous stasis ulcers.

    Treatment of Pathologic Perforators — Medical Necessity

    Medically necessary when ALL of the following are met

    Perforator treatment criteria (restate): Active venous stasis ulcer; recent duplex within 6 months demonstrating perforator reflux ≥500 ms and diameter ≥3.5 mm; perforator located in vicinity of active ulcer; saphenous veins draining ulcer area previously eliminated or do not exhibit pathologic reflux.reflux >=500 ms and diameter >=3.5 mm

    Treatment of pathologic perforators is not medically necessary for other pathology.

    Sclerotherapy (including non-compounded microfoam/Varithena) — Medical Necessity

    Sclerotherapy of truncal veins, incompetent tributaries, and perforator veins is considered medically necessary when ALL criteria are met

    Sclerotherapy criteria: Symptomatic reflux with CEAP C2+ or VCSS ≥6; venous duplex within 6 months showing pathologic truncal vein reflux ≥500 ms in required segments; absence of ipsilateral acute DVT or chronic multisegmental femoral-popliteal occlusion; adherence to truncal vein treatment limitations (max 2 truncal veins per extremity per session; additional treatment ≥12 weeks later unless active ulcer).duplex within 6 months; reflux >=500 ms

    Varithena manufacturer limit up to 15 mL/session.

    Sclerotherapy for truncal veins and incompetent tributaries

    Covered when ALL of the following are met

    Truncal/tributary sclerotherapy clinical criteria: Symptomatic reflux with CEAP C2+ or VCSS ≥6 AND venous duplex within 6 months demonstrating required reflux (≥500 ms per specified segments) AND absence of ipsilateral acute DVT or chronic multisegmental femoral-popliteal occlusion AND adherence to treatment limits (max 2 truncal veins per session; additional treatment ≥12 weeks later unless active ulcer).See node text

    Sclerotherapy of veins <3 mm medically necessary for spontaneous bleeding or corona phlebectatica.

    Treatment of varicose veins and tributaries

    Covered when ALL of the following are met

    Clinical severity: Symptomatic reflux with CEAP C2+ OR VCSS ≥6 with symptoms attributable to venous disease.
    Lesion size/reflux criteria: Recent venous duplex within 6 months demonstrating varicosities/tributaries ≥6 mm OR ≥3 mm with ≥500 ms reflux.>=6 mm OR >=3 mm with >=500 ms reflux
    Saphenous status: Saphenous veins have been previously eliminated or do not exhibit pathologic reflux when treating tributaries alone.
    Timing relative to saphenous ablation: Treatment may be performed concurrently with saphenous ablation OR if symptoms persist after 12 weeks observation following prior endovenous ablation (observation not required for venous ulcer cases).

    Treatment of pathologic perforators

    Covered when ALL of the following are met

    Perforator ulcer requirement: Active venous stasis ulcer is present; AND recent duplex within 6 months demonstrates perforator incompetence with reflux ≥500 ms AND vein diameter ≥3.5 mm; AND perforator is located in vicinity of the ulcer; AND saphenous veins draining the ulcer area have been previously eliminated or do not exhibit pathologic reflux.reflux >=500 ms and diameter >=3.5 mm

    Iliac vein / IVC angioplasty and stenting

    Covered when ANY of the following specific indications are documented

    Post-thrombotic residual stenosis: Acute iliofemoral DVT after thrombolysis or mechanical thrombectomy with underlying iliac vein or IVC compression demonstrating ≥50% residual stenosis.>=50% residual stenosis
    Non-thrombotic severe lesion with clinical sequelae: Non-thrombotic iliac vein or IVC lesion with ≥50% area reduction OR >60% diameter stenosis when associated with venous stasis ulceration, advanced stasis dermatitis, venous claudication, lifestyle-limiting asymmetric edema, or when no non-vascular cause is identified and venous collaterals are present.>=50% area reduction OR >60% diameter stenosis

    Failed 8-week conservative therapy required unless urgent.

    Conservative therapy requirement: Failed 8-week trial of conservative therapy (graded compression stockings, weight loss if applicable) demonstrated by no improvement, worsening, or limited improvement with continued lifestyle-limiting symptoms prior to stenting for non-thrombotic lesions.

    Upper extremity venous angioplasty/stenting (Thoracic Outlet Syndrome and related)

    Covered when ALL of the following are met

    Post-decompression and thrombolysis: Axillary/subclavian angioplasty/stenting is medically necessary following thrombolysis and decompression for associated musculoskeletal abnormality when acute axillary/subclavian DVT with compression results in significant residual stenosis (>30%).>30% residual stenosis

    Stenting rarely necessary except persistent stenosis resistant to angioplasty.

    Chronic/other indications: Non-thrombotic axillary or subclavian vein stenosis ≥50% with presence of venous collaterals is an indication for intervention.>=50% stenosis with collaterals

    Thoracic Outlet Syndrome (TOS)

    Covered when ALL of the following are met

    TOS angioplasty/stenting: Axillary or subclavian vein angioplasty/stenting is medically necessary following thrombolysis and surgical decompression for associated musculoskeletal abnormality when there is documentation of acute axillary and/or subclavian DVT with compression resulting in significant residual stenosis (>30%).>30% residual stenosis

    Stenting is rarely necessary except for persistent stenosis resistant to angioplasty.

    Hemodialysis Outflow Obstruction

    Venous angioplasty is covered when ANY of the following clinical conditions are present

    Hemodialysis outflow angioplasty indications: Presence of ipsilateral arm edema and/or venous claudication; inadequate hemodialysis performance (recirculation, aspiration of clot, inability to achieve target blood flow, prolonged bleeding after dialysis, development of large superficial collaterals, loss of thrill or pulsatile fistula/graft).clinical signs as listed

    Applies to procedures via punctures outside dialysis circuit.

    Hemodialysis venous stenting indications: Venous stenting is medically necessary when symptomatic recurrent >50% stenosis within 3 months of angioplasty; elastic recoil with residual stenosis >50%; or to cover pseudoaneurysm or dissection from prior intervention.>50% stenosis

    Applies to upper extremity outflow and central veins.

    Catheter or Cardiac Device Related Venous Outflow Obstruction

    Covered when ALL of the following are met

    Device-related angioplasty: >50% stenosis of the outflow vein or >50% ipsilateral central venous stenosis AND presence of ipsilateral arm edema and/or venous claudication.>50% stenosis

    Stenting should be avoided if indwelling device present as it may impede future manipulation/removal.

    Superior Vena Cava Syndrome

    Covered when BOTH of the following are met

    SVC syndrome angioplasty/stenting: >50% stenosis in the SVC AND either palliative care for malignancy OR (for non-malignant SVC syndrome) presence of lifestyle-limiting signs/symptoms (orthopnea, head/neck swelling, dizziness, blurred vision) AND failure of symptoms to resolve with conservative therapy (elevation, diuretics, anticoagulation).>50% stenosis

    Stenting often required for palliation in malignant cases.

    Left Renal Vein Compression (Nutcracker Syndrome)

    Covered when ALL of the following are met for re-intervention after surgery

    Nutcracker re-intervention: Recurrent left renal vein compression documented by imaging AND symptoms of left renal vein compression (eg, flank pain, hematuria, proteinuria) after prior surgical decompression.imaging-documented recurrent compression

    Primary endovascular treatment prior to surgical decompression is not medically necessary.

    Pulmonary Vein Stenosis

    Covered when ANY of the following imaging thresholds are met

    Pulmonary vein intervention: ≥60% narrowing of a pulmonary vein or an absolute stenosis diameter of 4–6 mm on advanced imaging (CTA, MRA, angiography) OR >50% stenosis identified on venogram or IVUS.>=60% narrowing or 4-6 mm absolute; OR >50% on venogram/IVUS

    Balloon angioplasty is initial treatment and may require repeat interventions.

    Hepatic Vein Thrombosis and Post-Transplant Interventions

    Covered when specific imaging thresholds or transplant criteria are met

    Hepatic vein/Budd-Chiari intervention: Thrombotic obstruction of major hepatic veins or IVC with >50% stenosis identified on venogram or IVUS.>50% stenosis

    Balloon angioplasty associated with good outcomes.

    Post-transplant arterial or venous intervention: Arterial stenosis ≥50% involving anastomosis/transplant artery or donor artery OR venous stenosis ≥30% involving anastomosis, portal vein or outflow vein for the transplanted organ on duplex, CT, MRI or angiography.arterial >=50%; venous >=30%

    Applies to listed transplanted organs.

    Nonthrombotic Iliac Vein Lesions (NIVLs)

    Coverage stance

    NIVL treatment: Iliac vein angioplasty/stenting is indicated for acute and chronic DVT related to NIVL causing symptomatic chronic edema, varicose veins, or venous stasis ulcers. Prophylactic treatment of NIVL in absence of acute/chronic DVT or symptomatic chronic edema and sequelae is not medically necessary.presence of acute/chronic DVT or symptomatic sequelae

    Prophylactic treatment is NMN.

    Arteriovenous Malformations

    Embolization is medically necessary when any one of the following applies:

    AVM Indications: Embolization/occlusion of cutaneous and/or deep tissue hemangioma or other vascular malformation is medically necessary when performed prior to planned surgery or stereotactic radiosurgery; when the lesion affects a vital structure (eg, nose, eyes, ears, lips, larynx); or when the lesion results in bleeding, high-output heart failure, pain, repeated infection, or interference with activities of daily living.

    Uterine Artery Embolization

    Uterine artery embolization is medically necessary to treat any of the following:

    UAE Indications: Abnormal placental implantation causing bleeding; postpartum hemorrhage after failure of uterotonic measures or surgery; uterine bleeding due to uterine AVM; uterine leiomyomas with abnormal uterine bleeding (including anemia or hemorrhage with normal endometrial sampling), dysmenorrhea unresponsive to analgesics causing impairment, dyspareunia >6 months not due to other pathology, or urinary symptoms from fibroid mass effect.

    Visceral Artery Aneurysm / Pseudoaneurysm

    Coil embolization is medically necessary when diagnostic imaging documents any of the following size/location criteria:

    Visceral aneurysm thresholds: Specific aneurysm size/location criteria including hepatic ≥2.0 cm; celiac ≥2.0 cm (and any celiac PSA any size); colic any size; gastric/gastroepiploic any size; jejunal/ileal ≥2.0 cm; SMA any size; pancreaticoduodenal/gastroduodenal any size; splenic ≥3.0 cm or any size if child-bearing potential; any size splenic PSA; renal ≥3.0 cm.see node text

    Imaging modality must be CTA, MRA, US, or angiogram.

    Embolization as an adjunct to EVAR

    Embolization is medically necessary in these adjunct situations:

    EVAR adjunct indications: Internal iliac (hypogastric) artery embolization prior to EVAR is necessary when a common iliac artery aneurysm requiring stenting to the level of the external iliac artery is identified pre-operatively; embolization of aortic side branches is medically necessary for a Type 2 endoleak with sac enlargement.

    Genicular Artery Embolization

    Genicular artery embolization is medically necessary when ALL of the following or specified conditions are met:

    Post-TKA or OA indications: History of total knee arthroplasty with hemarthrosis OR chronic pain with failed pain management and VAS ≥55 or WOMAC ≥40; OR osteoarthritis referred by a musculoskeletal specialist with KL Grade 1–3, VAS ≥55 or WOMAC ≥40, failure of ≥3 months conservative therapy, and not a candidate for TKA due to comorbidities (or KL Grade 4 with VAS/WOMAC thresholds).VAS >=55 or WOMAC >=40

    Failure of ≥3 months conservative therapy required for OA indications.

    Shoulder Joint Embolization

    Embolization is medically necessary for:

    Shoulder embolization indications: Individuals with hemarthrosis; OR adhesive capsulitis when physical exam is consistent, plain X-ray excludes other diagnoses, and there is failure of ≥3 months conservative therapy including topical/oral anti-inflammatories, steroid injection, and physical therapy/home exercise program.

    Hemorrhoid Embolization

    Endovascular embolization for hemorrhoids is medically necessary when ANY of the following apply after failed non-surgical treatment:

    Hemorrhoid embolization indications: Grade 1–3 hemorrhoids with recurrent bleeding episodes confirmed on anoscopy or no other bleeding source identified; OR Grade 1–3 hemorrhoids with symptoms other than bleeding in patients not candidates for in-office procedures or surgery due to comorbid illness (eg, anticoagulation, coagulopathy, immunosuppression, IBD); OR Grade 1–3 hemorrhoids with symptoms other than bleeding and failed prior interventions such as sclerotherapy or band ligation. Repeat embolization is medically necessary for recurrent daily rectal bleeding due to recurrent/persistent hemorrhoids.

    Failed non-surgical treatment required prior to embolization.

    Prostatic artery embolization (PAE)

    Covered when ALL of the following are documented:

    PAE eligibility: BPH with LUTS who have failed or cannot tolerate medical therapy AND one of: hematuria of prostatic origin; acute/chronic urinary retention with preserved bladder function to achieve catheter independence; severe LUTS (AUA ≥20) and prostate size ≥50 cm3; bladder outlet obstruction from intravesical prostate protrusion; OR individuals not surgical candidates due to advanced age, multiple comorbidities, coagulopathy, or inability to stop anticoagulation/antiplatelet therapy.AUA >=20; prostate >=50 cm3

    Repeat PAE may be indicated for recurrence after 6 months in selected individuals.

    Varicocele embolization

    Covered when ANY of the following are documented:

    Varicocele embolization indications: Management of infertility with palpable varicocele; OR recurrent varicocele; OR symptomatic varicocele causing pain or testicular swelling where embolization is chosen over surgical repair.

    Evidence supports improvement in sperm parameters and durability of pain relief.

    Oncologic and hemorrhage embolization

    Covered for tumor-directed or hemorrhage embolization when documented clinical indication exists:

    Oncologic embolization indications: Embolization for chemoembolization or cessation of bleeding in malignancy (eg, HCC, hepatic metastases, renal cell carcinoma, select thyroid metastases, localized giant cell tumor of bone) when clinically indicated.

    Use CPT 37243 for tumor/ischemia intent.

    Hemorrhage embolization indications: Embolization to control arterial or venous hemorrhage or extravasation when clinically indicated.

    Use CPT 37244 for hemorrhage control.

    Ovarian/pelvic vein embolization

    Covered when ALL of the following apply:

    Ovarian/pelvic vein embolization for PCS: Chronic pelvic pain >6 months with supportive symptoms (worse with standing/ walking, postcoital ache, dysmenorrhea, dyspareunia, bladder irritability, rectal discomfort, recurrent lower-extremity varicosities); no evidence of inflammatory disease; AND imaging supportive of pelvic congestion syndrome (US: tortuous pelvic veins >6 mm or slow/reversed flow; CT/MR: four ipsilateral tortuous para-uterine veins >4 mm or ovarian vein >8 mm).pelvic vein >6 mm (US) or ovarian vein >8 mm (CT/MR)

    Joint embolization (genicular, shoulder)

    Covered when documentation shows failure of conservative therapies and appropriate clinical selection:

    Genicular artery embolization (GAE): Knee osteoarthritis with pain refractory to medical therapy and injections; patient selection favors KL Grade 1–3 though KL 4 patients may gain symptom relief to delay TKA. Failure of ≥3 months conservative therapy and appropriate specialist referral expected.VAS >=55 or WOMAC >=40

    Evidence shows improvement in pain and function in selected patients.

    Shoulder joint embolization: Adhesive capsulitis with persistent pain and synovitis after ≥3 months conservative therapy, with physical exam and imaging/ X-ray excluding other diagnoses.>=3 months conservative therapy failure

    Used for patients not responding to steroid injection and therapy.

    Evidence-supported embolization indications

    Evidence-supported indications and clinical findings described in the citations:

    Varicocele evidence: Varicocele embolization supported by studies showing improvement in sperm parameters and durable pain relief up to 4 years.

    Citations include long-term cohort studies and guideline references.

    PAE evidence: Prostatic artery embolization (PAE) has growing evidence and multisociety position statements supporting its role for select individuals with LUTS/BPH.

    Cites SIR multisociety statements and systematic reviews.

    Pelvic vein embolization evidence: Pelvic vein embolization supported for V3a varices per AVLS working group report (Meissner et al., 2021).
    Genicular embolization evidence: Genicular artery embolization has emerging randomized and cohort evidence demonstrating pain reduction and improved function in selected OA patients with durability to ~2 years.

    CEA exclusion for disabling stroke

    Exclusion — carotid procedures

    CEA exclusion for disabling stroke: Carotid revascularization (CEA or CAS) is not medically necessary for individuals who have had a disabling stroke (modified Rankin scale ≥3).modified Rankin >=3

    Asymptomatic individuals should have adequate life expectancy to benefit.

    Placement of a permanent common carotid artery filter (sometimes described as a permanent carotid embolic protection device) is considered experimental, investigational, or unproven pending further evidence on safety, clinical efficacy, and long‑term stability. Documentation citing these uncertainties may be expected in prior‑authorization review.

    Endovascular angioplasty with stent placement of the extracranial vertebral artery is considered experimental, investigational, or unproven for indications beyond the specific, evidence‑based situations described in the policy. When vertebral artery stenting is proposed, the policy requires documentation that conservative/medical therapy has failed and that clinical and anatomic criteria supporting stenting are met; otherwise the procedure is not supported.

    Use of CPT 34718 (bifurcated‑bifurcated iliac endograft repair) for aorto‑iliac aneurysm repair is classified as experimental, investigational, and unproven because effectiveness for this approach has not been established; requests for this code may be denied on that basis.

    The policy extract does not list additional explicit procedural exclusions beyond the device‑ or procedure‑specific non‑indications described elsewhere. Coverage determinations are driven by the detailed size, symptomatic, and imaging criteria specified for each vascular condition (for example, visceral and popliteal aneurysm thresholds).

    Routine staging of interventions is not considered medically necessary unless the medical record documents a valid justification for staging. Acceptable reasons include patient instability, excessive fluoroscopy radiation exposure, inability to convert to general anesthesia due to unavailable resources, or projected contrast volume exceeding 200 mL. Absent one of these documented reasons, multiple planned stages may be denied.

    Percutaneous transluminal angioplasty (PTA) or stent placement in infrapopliteal vessels is generally not considered medically necessary except in rare intraoperative situations where it is deemed immediately necessary. Routine below‑knee stenting, atherectomy, or intravascular lithotripsy for infrapopliteal lesions—particularly for claudication or asymptomatic, non‑critical lesions (<50% stenosis)—is not supported by the evidence and is excluded from coverage.

    Intervention on inframalleolar and pedal arteries is limited to individuals with documented active ulcers or tissue loss and objective imaging demonstrating lack of distal arterial flow (for example GLASS P2 descriptors, occluded distal ATA/DP or PTA/tarsal branches, or pedal acceleration time >225 ms). Inframalleolar/pedal procedures are not indicated for patients with rest pain alone or for claudication.

    The policy explicitly excludes inframalleolar and pedal interventions for patients without active tissue loss: treatments for rest pain or claudication in the inframalleolar/pedal circulation are not considered medically necessary because available evidence does not demonstrate durable benefit in those populations.

    Treatment of pathologic perforator veins is limited. Perforator interventions are considered medically necessary only when associated with an active venous stasis ulcer and when duplex within 6 months documents perforator reflux ≥500 ms and diameter ≥3.5 mm; Varithena® is noted not to be FDA‑indicated for perforator vein treatment. For indications other than ulcer‑related healing, perforator therapy is not supported.

    Except when adjacent to an active venous stasis ulcer meeting the stated duplex and diameter criteria, intervention on perforator veins is not medically necessary. The policy requires that any saphenous reflux contributing to the ulcer area be treated or shown not to be pathologic prior to pursuing perforator treatment.

    The policy reiterates that perforator vein intervention is restricted to active venous stasis ulcer management and is not medically necessary for other clinical presentations (for example, isolated pain, cosmetic concerns, or uncomplicated varicosities). Varithena® is specifically called out as not FDA‑indicated for perforator treatment.

    Angioplasty or stenting of the left renal vein as primary treatment for Nutcracker syndrome is considered not medically necessary. The policy supports endovascular re‑intervention only for recurrent symptoms after prior surgical decompression; primary endovascular therapy prior to surgical decompression is excluded.

    Prophylactic embolization of aortic side branches (for example lumbar arteries or inferior mesenteric artery) solely to prevent a Type 2 endoleak prior to EVAR is explicitly listed as not medically necessary and is a non‑indication for embolization.

    Indications for vascular embolization that are not specifically supported by the guideline are considered not medically necessary due to lack of evidence. When embolization is proposed for a clinical indication not described in the policy, supporting literature and clear imaging/clinical rationale will be required but such requests may be denied if the indication is not included in the guideline.

    Within the provided fragments there are no additional standalone procedural exclusions beyond the device‑ and indication‑specific non‑indications already described (for example, permanent carotid filter, extracranial vertebral stenting for unsupported indications, CPT 34718). Coverage decisions are instead governed by the condition‑specific size, symptom, and imaging criteria summarized elsewhere in the policy.

    CPT/HCPCS Codes and Thresholds

    Carotid revascularization codesmixed
    37215Transcatheter placement of intravascular stent(s), cervical carotid artery; with distal embolic protection
    C8010Percutaneous placement of permanent common carotid embolic protection device, including all system components and imaging guidance; bilateral
    Iliac branched endograft (concurrent with aorto-iliac endograft)CPTCovered
    34717Endovascular repair of iliac artery at the time of aorto-iliac artery endograft placement by deployment of an iliac branched endograft, unilateral (List separately in addition to code for primary procedure)
    Iliac branched endograft (isolated)CPT
    34718Endovascular repair of iliac artery, not associated with placement of an aorto-iliac artery endograft at the same session, by deployment of an iliac branched endograft, unilateral
    Iliac revascularization angioplasty/stent codesCPTCovered
    37254Revascularization, endovascular, iliac vascular territory; transluminal angioplasty; straightforward lesion, initial vessel
    37256Revascularization, endovascular, iliac vascular territory; transluminal angioplasty; complex lesion, initial vessel
    37258Revascularization, endovascular, iliac vascular territory; transluminal stent placement; straightforward lesion, initial vessel
    37260Revascularization, endovascular, iliac vascular territory; transluminal stent placement; complex lesion, initial vessel
    37255Revascularization, endovascular, iliac vascular territory; transluminal angioplasty; each additional vessel (List separately)
    37261Revascularization, endovascular, iliac vascular territory; transluminal stent placement; complex lesion, each additional vessel (List separately)
    Visceral/popliteal and non-lower extremity stent codesCPTCovered
    37269Revascularization, endovascular, femoral and popliteal vascular territory; initial vessel
    37270Revascularization, endovascular, femoral and popliteal vascular territory; each additional vessel (List separately)
    37237Transcatheter placement of an intravascular stent(s) (except lower extremity), including angioplasty within the same vessel; each additional artery (List separately)
    Embolization codesCPTCovered
    37242Vascular embolization or occlusion; arterial, other than hemorrhage or tumor
    37244Vascular embolization or occlusion; for arterial or venous hemorrhage or lymphatic extravasation
    Peripheral non-coronary stent/angioplasty/atherectomy codesCPTCovered
    37236Transcatheter placement of an intravascular stent(s) (non-lower extremity), initial artery
    37237Transcatheter placement of an intravascular stent(s) (non-lower extremity), each additional artery
    37246Transluminal balloon angioplasty, initial artery (non-lower extremity)
    37254Revascularization, endovascular, iliac vascular territory, angioplasty; straightforward lesion, initial vessel
    37255Revascularization, endovascular, iliac vascular territory, angioplasty; each additional vessel
    37256Revascularization, endovascular, iliac vascular territory, angioplasty; complex lesion, initial vessel
    37257Revascularization, endovascular, iliac vascular territory, angioplasty; complex lesion, each additional vessel
    37262Intravascular lithotripsy, iliac vascular territory
    37263Revascularization, femoral/popliteal territory, angioplasty; initial vessel
    37264Revascularization, femoral/popliteal territory, angioplasty; each additional vessel
    1–10 of 17
    1/2
    Covered CPT Codes (excerpted)CPTCovered
    37271Revascularization, endovascular, femoral and popliteal vascular territory, with transluminal atherectomy; straightforward lesion, initial vessel
    37272Revascularization, endovascular, femoral and popliteal vascular territory; each additional vessel (atherectomy)
    37276Revascularization... stent placement with atherectomy/angioplasty, each additional vessel (referenced)
    37280Revascularization, tibial and peroneal vascular territory, with transluminal angioplasty
    37281Revascularization, tibial and peroneal vascular territory, angioplasty; each additional vessel
    37282Revascularization, tibial and peroneal vascular territory, angioplasty; complex lesion
    37283Revascularization, tibial and peroneal vascular territory, angioplasty; complex lesion, each additional vessel
    37285Revascularization, tibial and peroneal vascular territory, stent placement; each additional vessel
    37286Revascularization, tibial and peroneal vascular territory, stent placement; complex lesion, initial vessel
    37287Revascularization, tibial and peroneal vascular territory, stent placement; complex lesion, each additional vessel
    1–10 of 14
    1/2
    Intravascular lithotripsy HCPCSHCPCSCovered
    C9764Revascularization, lower extremity artery(ies), except tibial/peroneal; with intravascular lithotripsy, includes angioplasty within the same vessel(s)
    C9765Revascularization, lower extremity artery(ies), except tibial/peroneal; with intravascular lithotripsy and transluminal stent placement(s), includes angioplasty within the same vessel
    C9766Revascularization, lower extremity artery(ies), except tibial/peroneal; with intravascular lithotripsy and atherectomy, includes angioplasty within the same vessel(s)
    C9775Revascularization, tibial/peroneal artery(ies); with intravascular lithotripsy and transluminal stent placement(s), and atherectomy, includes angioplasty within the same vessel(s), when performed
    Endovenous ablation, sclerotherapy, ligation/stripping codesCPTCovered
    36475Endovenous ablation therapy of incompetent vein, extremity, radiofrequency; first vein
    36476Endovenous ablation therapy of incompetent vein, extremity, radiofrequency; subsequent vein(s)
    36478Endovenous ablation therapy of incompetent vein, extremity, laser; first vein
    36482Endovenous ablation therapy by transcatheter delivery of a chemical adhesive; first vein
    36483Endovenous ablation therapy by transcatheter delivery of a chemical adhesive; subsequent vein(s)
    36473Endovenous ablation therapy mechanochemical; first vein
    36474Endovenous ablation therapy mechanochemical; subsequent vein(s)
    36470Injection of sclerosant; single incompetent vein (other than telangiectasia)
    36471Injection of sclerosant; multiple incompetent veins (other than telangiectasia), same leg
    37700Ligation and division great saphenous vein at saphenofemoral junction, or distal interruptions
    1–10 of 14
    1/2
    Non-compounded foam sclerotherapy - single truncal veinCPTCovered
    36465Injection of non-compounded foam sclerosant with ultrasound compression maneuvers; single incompetent extremity truncal vein
    Non-compounded foam sclerotherapy - multiple truncal veins same legCPTCovered
    36466Injection of non-compounded foam sclerosant with ultrasound compression maneuvers; multiple incompetent truncal veins, same leg
    Covered CPT Code - single truncal veinCPTCovered
    36465Injection of non-compounded foam sclerosant with ultrasound compression maneuvers; single incompetent extremity truncal vein
    Covered CPT Code - multiple truncal veins same legCPTCovered
    36466Injection of non-compounded foam sclerosant with ultrasound compression maneuvers; multiple incompetent truncal veins, same leg
    Procedure and injection CPT codes mentionedCPTCovered
    37700Ligation and division long saphenous vein at saphenofemoral junction, or distal interruptions
    37718Ligation, division, and stripping, short saphenous vein
    37722Ligation, division, and stripping, long (greater) saphenous veins from saphenofemoral junction to knee or below
    37735Ligation, division and complete stripping of long or short saphenous veins with radical excision of ulcer and skin graft and/or interruption of communicating veins
    37760Ligation of perforator veins, subfascial, radical (Linton type), including skin graft, when performed, open, 1 leg
    37761Ligation of perforator vein(s), subfascial, open, including ultrasound guidance, when performed, 1 leg
    37765Stab phlebectomy of varicose veins, one extremity; 10-20 stab incisions
    37766Stab phlebectomy of varicose veins, one extremity; more than 20 incisions
    37780Phlebectomy (unspecified description in document)
    37785Ligation, division, and/or excision of varicose vein cluster(s), 1 leg
    1–10 of 15
    1/2
    Iliac/venous angioplasty and stenting CPT codesCPT
    37238Transcatheter placement of an intravascular stent(s), initial vein
    37239Transcatheter placement of an intravascular stent(s); each additional vein
    37248Transluminal balloon angioplasty; initial vein
    37249Transluminal balloon angioplasty; each additional vein
    Hemodialysis Outflow Procedure CodesCPTCovered
    37238Transcatheter placement of an intravascular stent(s); initial vein
    37248Transluminal balloon angioplasty; initial vein
    Codes referenced in policy sectionsmixed
    No codes listed
    Recommended embolization CPT codesCPTCovered
    37241Vascular embolization or occlusion; venous, other than hemorrhage (e.g., venous malformations, hemangiomas, varices, varicoceles)
    37242Vascular embolization or occlusion; arterial, other than hemorrhage or tumor
    37243Vascular embolization or occlusion; for tumors, organ ischemia, or infarction (including UAE, PAE, oncologic embolization)
    37244Vascular embolization or occlusion; for arterial or venous hemorrhage or active bleeding
    inv-109: High-grade stenosis threshold
    Definition (policy)High-grade stenosis is defined as at least a 50% narrowing of an artery.
    Numeric threshold>= 50%
    Contextual useUsed as the imaging threshold to define lesions not eligible for routine elective intervention when <50% and to trigger intervention when >=50% in many arterial indications.

    Prior Authorization, Documentation, and Operational Guidance

    Prior Authorization

    Submit PA ≥2 weeks with complete clinical and imaging documentation

    Submit prior-authorization at least two weeks before an elective procedure and include documentation of: the proposed procedure matching clinical need; the condition being treated; detailed prior provider-directed conservative therapy (duration, frequency, response); prior interventions and response; aneurysm location/size if present; nature of critical limb ischemia (non-healing wound or ischemic rest pain) when applicable; and recent (within 6 months) diagnostic imaging reports and clinical evaluation (e.g., ABIs, duplex, CTA/MRA, angiogram, IVUS, symptoms, physical exam, ulcer details).

    • Prior-authorization requests should be submitted at least two weeks prior to an elective surgery.
    • Include recent (within 6 months) imaging reports (duplex, CTA/MRA/angiogram/IVUS) and clinical evaluation documenting symptoms and exam (e.g., ulcer size/location).
    • Provide detailed conservative therapy history and prior procedural history with responses.
    Documentation Required

    Background and Scope

    Background: Peripheral vascular interventions address arterial stenosis or occlusion, aneurysmal disease, and venous pathology with the goals of restoring perfusion, preventing rupture, or treating symptomatic venous disease. Urgent or emergent clinical scenarios (for example, critical limb ischemia, symptomatic carotid stenosis, crescendo TIAs, symptomatic or ruptured aneurysms) may bypass routine conservative management and warrant timely definitive revascularization; otherwise, treatment indications rely on objective imaging thresholds (for example, stenosis ≥50% defines high‑grade disease) and documented clinical symptoms or tissue loss to demonstrate medical necessity.

    Definitions and Key Terms

    inv-199: High-grade stenosis
    High-grade stenosis (definition)High-grade stenosis defined as >=50% narrowing of an artery; used to classify lesions for intervention consideration.
    Critical limb ischemia (definition)Severe stenosis/occlusion that risks limb loss; includes non-healing wounds, gangrene, ischemic rest pain.
    Aneurysm (definition)Diameter 1.5x normal arterial diameter.
    inv-200: Critical limb ischemia
    CLI criteria (summary)Critical limb ischemia requires documentation of non-healing ischemic/mixed wounds >2 weeks, gangrene needing revascularization for minor amputation, or ischemic rest pain with ABI <0.5 (non-diabetics) or TBI <0.6/monophasic waveforms in diabetics; imaging confirming >=50% stenosis.
    Imaging threshold

    Policy Revision History

    2026-11-05policy_effective_dateLatest

    Policy version v2.0 (PVI.100.A) became effective; guideline content and coding references (including CPT embolization coding guidance) published.

    2026-05-05reference_publication

    Guidance on correct embolization coding (Buck SL) published and later cited in the policy bibliography.

    Policy Summary
    Payerevicore
    PolicyPeripheral Vascular Intervention (PVI) — carotid and arterial revascularization guidance
    Policy CodePolicy PVI.100.A
    Change TypeNo material change
    Effective DateNov 5, 2026
    Next Review Date
    Key ActionSubmit prior-authorization at least two weeks before elective procedures with recent diagnostic imaging (within 6 months) and documentation of conservative therapy and clinical findings to support medical necessity.
    SourceLink
    On This Page
    Coverage Criteria and Medical NecessityCPT/HCPCS Codes and ThresholdsPrior Authorization, Documentation, and Operational GuidanceBackground and ScopeDefinitions and Key TermsPolicy Revision History
    any one triggers coverage

    Permits re-intervention in asymptomatic high-grade stenosis.

    >=12 weeks if staged

    concurrent treatment allowed

    Sclerotherapy veins <3mm: Sclerotherapy for veins <3 mm is medically necessary for spontaneous bleeding from a varix OR corona phlebectatica.
    >=8 weeks
    Pelvic congestion syndrome with labial/vaginal varicosities and pain/swelling/bleeding with imaging evidence meeting thresholds (≥50% area reduction by IVUS OR >60% diameter stenosis with collaterals) qualifies for intervention; iliac stenting can be staged or concurrent with ovarian vein embolization when criteria met.imaging thresholds as stated

    Multiple recent studies cited.

    Hemorrhoid embolization evidence: Catheter-directed hemorrhoidal embolization shows promising technical success and variable recurrence rates; may be medically necessary for selected patients per registry and reviews.

    Evidence limited; further study recommended.

    inv-110: Recency window for diagnostic imaging and clinical evaluation
    Recency windowDiagnostic imaging and clinical evaluation must be completed within 6 months prior to the scheduled procedure.
    Required itemsAcceptable diagnostic studies include duplex ultrasound, CTA/MRA, arteriogram/venogram, ABI/segmental pressures/PVRs, and IVUS as applicable.
    Prior-authorization timingPrior-authorization requests should be submitted at least two weeks before an elective surgery.
    inv-111: Stenosis and duplex thresholds
    Symptomatic carotid stenosis (CEA)>= 50% stenosis by angiogram, CTA, carotid duplex, or MRA (meets criteria for CEA).
    Asymptomatic carotid stenosis (CEA)>= 70% stenosis by NASCET criteria on carotid duplex, CTA, MRA, or angiogram within 6 months.
    Recurrent carotid stent restenosis (duplex PSV)Symptomatic: PSV >= 240 cm/sec; Asymptomatic: PSV >= 370 cm/sec (or corresponding imaging evidence of >=50% or >=70% respectively).
    inv-112: Common iliac artery aneurysm diameter
    Common iliac artery aneurysm diameter threshold> 3.5 cm (ipsilateral common iliac artery aneurysm for consideration of CPT 34717 when concurrent AAA repair planned).
    Procedural contextThreshold applies when an iliac branched endograft (CPT 34717) is planned at time of aorto-iliac endograft placement; documentation of all criteria required.
    inv-113: Internal iliac artery aneurysm diameter (asymptomatic)
    Asymptomatic internal iliac artery aneurysm threshold>= 3.0 cm (endovascular intervention considered medically necessary).
    Other indicationsSymptomatic internal iliac aneurysm of any size or evidence of bleeding (active extravasation) also supports intervention.
    inv-114: Popliteal artery aneurysm diameter for asymptomatic repair
    Asymptomatic popliteal aneurysm repair threshold>= 2.0 cm on ultrasound, CT, or MRI.
    Symptomatic popliteal aneurysm criteria>= 1.5 cm on US/CT/MR PLUS documented mural thrombus within the aneurysm AND evidence of new onset claudication, critical limb-threatening ischemia, or blue toe syndrome.
    Definition notePopliteal aneurysm defined as >1.5 cm or 1.5× normal (normal 5–9 mm); risk increases with size and thrombus formation.
    inv-115: Popliteal artery aneurysm diameter for symptomatic repair
    Symptomatic repair actionable threshold>= 1.5 cm on ultrasound, CT, or MRI plus documentation of mural thrombus and ischemic symptoms (new claudication, CLI, or blue toe syndrome).
    Imaging requirementAneurysm diameter and mural thrombus must be documented on US, CT, or MRI.
    inv-116: Visceral artery aneurysm/pseudoaneurysm size thresholds (examples)
    Hepatic artery aneurysm>= 2.0 cm (coil embolization indicated).
    Splenic artery aneurysm>= 3.0 cm OR any size in individuals with child-bearing potential; any splenic pseudoaneurysm size treated as indicated.
    Renal artery aneurysm>= 3.0 cm (coil embolization indicated).
    inv-117: Contrast volume
    Contrast volume justification for staging> 200 mL (full dose contrast volume greater than 200 mL is a valid justification for staging procedures).
    Staging policyStaging of interventions is not medically necessary unless a valid justification (e.g., patient instability, excessive fluoroscopy, unavailable anesthesia resources, or contrast >200 mL) is documented.
    inv-118: Pedal acceleration time (PAT)
    Pedal acceleration time (PAT)>225 ms (PAT >225 ms supports inframalleolar/pedal intervention in the setting of active tissue loss).
    Clinical contextPAT >225 ms is an imaging/physiologic finding used to support inframalleolar angioplasty when active tissue loss and lack of distal flow are present.
    inv-119: Imaging stenosis threshold
    General imaging stenosis threshold>= 50% stenosis by objective imaging (CTA/MRA/angiogram/duplex) for many indications to support intervention.
    Usage examplesUsed for claudication initial treatment, CLI, and many revascularization indications as the imaging threshold for intervention.
    inv-120: Venous duplex reflux
    Venous duplex reflux duration threshold>= 500 ms (reverse flow lasting >=500 ms defines pathologic truncal vein reflux).
    ApplicationRequired duplex criterion for saphenous truncal vein treatment, non-compounded foam sclerotherapy, and other venous interventions (segment-specific rules apply).
    inv-121: Perforator vein diameter
    Perforator vein diameter threshold>= 3.5 mm when adjacent to an active venous stasis ulcer (with reflux >=500 ms) to qualify for perforator treatment.
    Combined criteriaPerforator treatment requires active ulcer, duplex within 6 months showing reflux >=500 ms and diameter >=3.5 mm, and perforator located near the ulcer.
    inv-122: Duplex reflux duration
    Duplex reflux duration>= 500 ms (reverse flow lasting >=500 ms on venous duplex).
    RelevanceDefines significant truncal or perforator reflux used across sclerotherapy, ablation, phlebectomy, and perforator treatment criteria.
    inv-123: Perforator vein diameter duplicate
    Perforator vein diameter (duplicate)>= 3.5 mm for perforator incompetence adjacent to active ulcer with reflux >=500 ms.
    DocumentationRequires recent duplex (within 6 months) demonstrating both diameter and reflux criteria and anatomical proximity to ulcer.
    inv-124: Maximum Varithena foam volume
    Maximum Varithena foam volumeUp to 15 mL per manufacturer's literature per treatment session.
    Product noteVarithena is a commercially manufactured polidocanol microfoam (1%); physician-compounded Tessari foam has not been shown inferior for varicose vein treatment.
    inv-125: Reflux duration
    Reflux duration threshold (duplicate)>= 500 ms (used across truncal, perforator, and sclerotherapy criteria).
    Clinical useRequired on venous duplex within 6 months to support saphenous or perforator treatment; segment-specific minima apply (eg, >=2 segments for above-knee GSV).
    inv-126: Perforator vein diameter for ulcer treatment
    Perforator diameter for ulcer treatment>= 3.5 mm (with reflux >=500 ms and proximity to active venous stasis ulcer).
    Required sequencingSaphenous veins draining the ulcer area should be eliminated or not exhibit pathologic reflux before perforator treatment.
    inv-127: Tributary size
    Tributary size threshold>= 6 mm OR >= 3 mm with >=500 ms reflux (for phlebectomy or treatment of tributaries).
    Timing/indicationTributaries may be treated concurrently with saphenous ablation or after 12 weeks if symptoms persist (observation period not required for ulcers).
    inv-128: Duplex recency
    Duplex recency requirementVenous duplex must be completed within 6 months prior to the scheduled venous procedure.
    Applies toSaphenous vein ablation, sclerotherapy, perforator treatment, phlebectomy, and related venous interventions.
    inv-129: Imaging and physiologic thresholds
    Examples of imaging & physiologic thresholdsTruncal reflux >=500 ms; varicosity/tributary diameter >=6 mm (or >=3 mm with >=500 ms reflux); perforator diameter >=3.5 mm with >=500 ms reflux; iliac/IVC >=50% area reduction or >60% diameter stenosis.
    ContextThese thresholds are applied to define pathologic venous disease and to support medical necessity for venous and iliac interventions.
    inv-130: Stenosis and diameter thresholds
    Common stenosis and diameter thresholds>30% residual stenosis (post thrombolysis in TOS); >50% stenosis for many arterial/venous interventions; ≥50% arterial stenosis post-transplant; ≥30% venous stenosis post-transplant; ≥60% pulmonary vein narrowing or absolute diameter 4-6 mm.
    Application examplesUsed for thoracic outlet, catheter/device related obstruction, post-transplant interventions and pulmonary vein stenosis decisions.
    inv-131: Visceral artery aneurysm size thresholds
    Visceral artery aneurysm size thresholds (summary)Hepatic >=2.0 cm; Celiac >=2.0 cm (and any celiac pseudoaneurysm any size); jejunal/ileal >=2.0 cm; SMA, pancreaticoduodenal, gastroduodenal any size; splenic >=3.0 cm (or any size if child-bearing potential) or any splenic PSA; renal >=3.0 cm.
    Imaging modalitiesCTA, MRA, US, or angiogram required to document aneurysm size/location prior to coil embolization.
    inv-132: Genicular symptom and imaging thresholds
    Genicular symptom thresholdsVAS >=55 or WOMAC >=40 and failure of >=3 months conservative therapy; KL Grade 1-3 preferred selection (KL 4 considered in select circumstances).
    DocumentationReferral by a musculoskeletal specialist and documentation of conservative therapy attempts required.
    inv-133: Prostate volume
    Prostate volume threshold for PAE>= 50 cm^3 (prostate size documented and severe LUTS or other supporting criteria).
    Additional criteriaSevere LUTS (AUA >=20), hematuria of prostatic origin, or urinary retention with preserved bladder function are among indications when medical therapy fails/intolerant.
    inv-134: Pelvic vein diameter (ultrasound)
    Pelvic vein diameter on ultrasound> 6 mm (tortuous pelvic veins >6 mm supports pelvic congestion syndrome and embolization).
    Imaging alternativesCT/MR criteria include four ipsilateral tortuous para-uterine veins >4 mm or ovarian vein diameter >8 mm.
    inv-135: Para-uterine vein diameter (CT/MR)
    Para-uterine vein diameter on CT/MR> 4 mm for four ipsilateral para-uterine veins OR ovarian vein > 8 mm (CT/MR criteria supporting pelvic congestion syndrome).
    Clinical contextChronic pelvic pain >6 months with supportive symptoms and absence of inflammatory disease required to support embolization.
    inv-136: Severe LUTS (AUA score)
    Severe LUTS (AUA score)AUA score >= 20 (severe lower urinary tract symptoms supports consideration of PAE when medical therapy failed/intolerant).
    Combined criteriaSevere LUTS often paired with prostate size >=50 cm^3 or other clinical indications (hematuria, retention) to justify PAE.
    inv-137: Prior-authorization timing and documentation (coding-relevant)
    Submission timingSubmit prior-authorization requests at least two weeks prior to an elective surgery.
    Required documentation listInclude procedure proposed, condition treated, prior conservative treatments and responses, prior interventions and responses, aneurysm location/size if present, CLI details (non-healing wound/ischemic rest pain), and recent diagnostic imaging/clinical evaluation within 6 months.
    Urgent requestsFor urgent/emergent conditions (CLI, symptomatic carotid stenosis, crescendo TIAs, symptomatic/ruptured aneurysms), emergent requests are processed per standards and prior authorization timing expectations differ.

    Facility/operator competency and embolic protection expectations for CAS/TCAR

    Ensure carotid stenting (CAS/TCAR) is performed in facilities that meet CMS competency expectations — documented physician training, facility support, and outcome data collection — and use embolic protection when indicated.

    • CAS with embolic protection should be performed in facilities competent in evaluation, procedure, and follow-up per CMS standards.
    • Maintain documentation of physician training, facility support, and outcomes data as applicable.
    Prior Authorization

    PA required for iliac branched endograft (CPT 34717) — document concurrent AAA and size criteria

    Obtain prior authorization when billing iliac branched endograft (CPT 34717) and related iliac endovascular repair codes; clinical documentation must meet the CPT 34717 medical necessity criteria (concurrent AAA repair planned, ipsilateral common iliac aneurysm >3.5 cm, and contralateral IIA occlusion).

    • CPT 34717 requires documentation that AAA repair is planned concurrently, ipsilateral common iliac aneurysm >3.5 cm, and contralateral internal iliac artery occlusion.
    • Prior authorization must be submitted with imaging and clinical history supporting those criteria.
    Prior Authorization

    Obtain PA using the specific CPT code(s) for peripheral vascular interventions

    Request prior authorization for the listed non-coronary peripheral vascular CPT codes relevant to the planned procedure and include procedure-specific imaging and clinical indication in the request.

    • Prior authorization is tied to specific CPT codes for non-coronary peripheral vascular interventions; submit the specific code(s) planned with supporting imaging and clinical rationale.
    • Examples of covered code families include femoral/popliteal angioplasty/stent (e.g., 37263–37269) and atherectomy (37271–37273).
    Billing Rule

    Include listed CPT and HCPCS codes (e.g., IVL C-codes) in PA request

    Follow payer prior-authorization processes for the listed revascularization CPT codes and intravascular lithotripsy HCPCS codes; request authorization using the applicable CPT/HCPCS (e.g., 37271–37299, C9764–C9775) when indicated.

    • Prior authorization is relevant for the listed revascularization CPT codes (e.g., 37271–37299).
    • Intravascular lithotripsy HCPCS codes (C9764–C9775) should be included in PA requests when IVL is planned.
    Prior Authorization

    Authorization must include failed conservative therapy, surveillance data, and lesion-specific imaging

    Include evidence required to support authorization: failed conservative therapy for claudication (3 months), surveillance data (ABI drop, duplex PSV/velocity ratios), and imaging confirming lesion-specific thresholds (e.g., ≥50% stenosis); inframalleolar cases require documentation of active tissue loss and lack of distal flow or PAT >225 ms.

    • For claudication, document a failed 3‑month trial of provider-directed conservative therapy and imaging confirming ≥50% stenosis.
    • For repeat intervention provide surveillance triggers (ABI drop ≥0.15, duplex PSV thresholds, ≥50% imaging stenosis).
    • Inframalleolar interventions require active tissue loss and imaging showing occluded distal vessels or PAT >225 ms.
    Prior Authorization

    PA required for endovenous ablation — document CEAP/VCSS and qualifying duplex within 6 months

    Obtain prior authorization for endovenous ablation and related saphenous vein procedures; include documentation of symptomatic venous disease (CEAP ≥ C2 or VCSS ≥6) and a venous duplex completed within 6 months demonstrating pathologic truncal vein reflux (≥500 ms) per segment-specific rules.

    • Document CEAP classification ≥ C2 or VCSS ≥6 and symptoms attributable to venous disease.
    • Submit recent venous duplex (within 6 months) showing truncal vein reflux ≥500 ms with required segment counts (e.g., ≥2 segments for above-knee GSV).
    Prior Authorization

    PA required for non‑compounded foam sclerotherapy (CPT 36465, 36466)

    Prior authorization is required per payer processes for non-compounded foam sclerotherapy codes: CPT 36465 (single incompetent truncal vein) and CPT 36466 (multiple truncal veins, same leg).

    • Use CPT 36465 for injection of non-compounded foam sclerosant to a single truncal vein.
    • Use CPT 36466 for multiple truncal veins in the same extremity; include required clinical and duplex documentation in the PA.
    Billing Rule

    Include procedure-specific CPT codes and supporting evidence for venous/open procedures

    When requesting authorization for saphenous trunk, tributary, perforator, phlebectomy, or open ligation/stripping procedures, submit the specific CPT codes listed and supporting clinical/imaging evidence demonstrating medical necessity.

    • Examples of codes include 36468, 36470–36471, 37700, 37718, 37722, 37735, 37760–37766, 37780, 37785, 37799.
    • Include duplex results, CEAP/VCSS, and history of prior conservative or ablation therapy as applicable.
    Prior Authorization

    PA required for venous stent/angioplasty codes (e.g., 37238, 37248) with imaging and conservative therapy documentation

    Prior authorization applies to venous stent and angioplasty CPT codes (e.g., 37238, 37239, 37248, 37249); include imaging and clinical criteria demonstrating indication (e.g., ≥50% area reduction or >60% diameter stenosis for iliac/IVC lesions, failed conservative therapy for 8 weeks when applicable).

    • CPT 37238/37239 for venous stent placement and CPT 37248/37249 for venous angioplasty require PA per payer process.
    • Support PA with IVUS/venogram/CT/MR demonstrating stenosis thresholds and documentation of failed conservative therapy when required.
    Prior Authorization

    PA for hemodialysis outflow angioplasty/stenting — document clinical dialysis-related criteria

    For hemodialysis outflow procedures (e.g., CPT 37238, 37248) request prior authorization when clinical criteria for outflow obstruction are present (ipsilateral arm edema, inadequate dialysis performance, loss of thrill, large collaterals) and when stenting criteria (recurrent >50% stenosis within 3 months, elastic recoil, pseudoaneurysm coverage) apply.

    • Document clinical signs of outflow obstruction (arm edema, dialysis recirculation, inability to achieve target blood flow, prolonged bleeding, loss of thrill).
    • Stenting indications include symptomatic recurrent >50% stenosis within 3 months of angioplasty or elastic recoil with residual >50% stenosis.
    Prior Authorization

    PA required for embolization — include indication‑specific imaging and specialist documentation

    Prior authorization is expected for embolization procedures; the request must reference the specific clinical indication and supporting imaging or specialist documentation (e.g., size criteria for visceral aneurysms, failure of conservative therapy for genicular embolization, anoscopy for hemorrhoids).

    • Provide diagnostic imaging and indication-specific documentation (CTA/MRA/US/angiogram for aneurysm sizes; specialist referral notes for joint embolization).
    • For hemorrhoid embolization include anoscopy confirmation of recurrent bleeding or documentation of failed nonsurgical therapy.
    Billing Rule

    Preauthorize the single embolization CPT code matching the primary intent (37241–37244); document separate fields

    Select and preauthorize the single CPT embolization code that corresponds to the primary clinical intent and vessel type (e.g., CPT 37241–37244); if multiple distinct anatomical treatment fields are performed, document them separately to allow independent reporting.

    • Coding selection should be driven by the dominant therapeutic intent (venous malformations 37241; arterial non-hemorrhage 37242; tumor/organ ischemia 37243; hemorrhage 37244).
    • When multiple separate anatomical areas are treated, document separate operative fields clearly to permit reporting of each area.
    Billing Rule

    Accurate embolization CPT selection (37241–37244) required to support PA and avoid audit

    Ensure embolization coding accuracy: use the appropriate CPT code (37241–37244) that matches the billed procedure and primary intent to support authorization and claims processing; incorrect coding may trigger audit or denial.

    • Use CPT 37241 for venous malformations/varices/varicoceles; 37242 for arterial embolization other than hemorrhage/tumor; 37243 for tumor/organ ischemia; 37244 for hemorrhage control.
    • Only one primary embolization code per treatment field should be reported; document intent and vessel type in the PA.
    Note

    Urgent/emergent requests: document condition and imaging; conservative therapy not required

    For urgent or emergent clinical indications (e.g., critical limb ischemia, symptomatic carotid stenosis, crescendo TIAs, symptomatic or ruptured aneurysms), emergent requests may be processed without prior conservative management; document urgency and supporting imaging/clinical evidence per NCQA standards.

    • Provider-directed non-surgical management is not required when documentation supports urgent/emergent conditions such as critical limb ischemia or symptomatic carotid stenosis.
    • Follow NCQA urgent/emergent determination criteria and include supporting imaging/clinical assessment in the request or retrospective documentation as applicable.
    Prior Authorization

    Vertebral artery stenting requires prior medical therapy failure and symptom/imaging correlation

    For extracranial vertebral artery stenting document failure of antiplatelet or anticoagulation therapy, exclusion/management of non-vascular etiologies, and ongoing posterior circulation symptoms; authorization is indicated only after these prerequisites are met.

    • Document prior medical therapy failures (antiplatelet/anticoagulation) and exclusion of non-vascular causes.
    • Provide imaging demonstrating 60–99% extracranial vertebral artery stenosis and correlate with clinical symptoms.
    Documentation Required

    Document intraoperative treatment escalation and clinical rationale in operative report

    Document intraoperative rationale when treatment is escalated (e.g., additional levels treated) due to operative findings; include intraoperative notes describing the decision-making and that additional levels were necessary.

    • If intraoperative findings change the planned procedure, include operative report details explaining the escalation.
    • Document why additional levels or devices were required to support claims and authorization adjudication.
    Step Therapy

    Require 3‑month trial of provider‑directed conservative therapy for claudication prior to PA

    For claudication, document a trial of at least 3 months of provider-directed conservative therapy (including structured exercise program if available) with documented follow-up prior to authorization for intervention.

    • Conservative therapy must be documented with duration, modalities attempted, and clinical response.
    • If structured exercise programs are unavailable locally, document provider-directed exercise counseling and follow-up.
    Step Therapy

    Document prior conservative venous management and symptom attribution before PA

    Expect conservative management attempts for venous disease where appropriate (e.g., compression, elevation, exercise) and document symptom persistence and why intervention is clinically indicated rather than cosmetic.

    • Document that symptoms are attributable to venous disease (not cosmetic) and conservative measures were attempted when applicable.
    • Include CEAP/VCSS scores and duplex results to correlate symptoms with pathology.
    Documentation Required

    Document valid justification for staged procedures (contrast >200 mL, instability, excess fluoroscopy, anesthesia limits)

    When staging procedures, document valid justification in the medical record (e.g., patient instability, excess fluoroscopy, need to convert to general anesthesia with unavailable resources, or contrast volume >200 mL); absent valid justification, staged procedures may be denied.

    • Valid reasons for staging include patient instability, fluoroscopy exceeding safe dosage, unavailable anesthesia resources for conversion, or contrast volume >200 mL.
    • Document the justification clearly in the medical record to support staged treatment.
    Step Therapy

    Require failed 8‑week conservative trial before iliac vein stenting (unless urgent post‑thrombolysis indication)

    Iliac vein interventions require documentation of failure of an 8‑week trial of conservative therapy (graded compression, weight loss if applicable) prior to stenting for non-thrombotic lesions unless urgent indications (e.g., post-thrombolysis residual stenosis) are present.

    • Record duration and modalities of conservative therapy and objective lack of improvement before PA for NIVL.
    • If urgent/acute post-thrombolysis residual stenosis (≥50%) exists, document the urgency to bypass the conservative trial requirement.
    Step Therapy

    Trial of conservative therapy for non‑malignant SVC syndrome required prior to intervention

    For non-malignant SVC syndrome, document failure of conservative therapy (elevation, diuretics, anticoagulation) before angioplasty/stenting; for malignant SVC syndrome, palliative interventions may proceed per clinical need.

    • Document conservative measures attempted and their lack of symptomatic resolution for non-malignant SVC syndrome.
    • Palliative stenting for malignancy is allowable with appropriate documentation.
    Step Therapy

    Require ≥3 months failed conservative therapy for joint-related embolization prior to PA

    For musculoskeletal/joint embolization (e.g., genicular, shoulder), document failure of specified conservative therapies (typically ≥3 months) or prior procedure attempts before authorization is considered.

    • Genicular embolization requires failure of ≥3 months of conservative therapy and appropriate pain/function scores (VAS ≥55 or WOMAC ≥40) when applicable.
    • Shoulder embolization for adhesive capsulitis requires ≥3 months conservative therapy failure and confirmatory exam/imaging.
    Step Therapy

    Require failed prior conservative therapy for hemorrhoid embolization and PAE; include anoscopy/AUA/prostate size evidence

    Embolization for hemorrhoids or PAE should be requested only after failure or intolerance of prior nonsurgical therapies (e.g., dietary/lifestyle changes, medical therapy for BPH); include documentation of prior attempts and indication-specific findings (anoscopy for hemorrhoids, AUA score/prostate size for PAE).

    • For hemorrhoid embolization include evidence of failed non-surgical treatment and anoscopic confirmation of bleeding when indicated.
    • For PAE, document failure/intolerance of medical therapy and prostate metrics (AUA score ≥20 or prostate size ≥50 cm3) per criteria.
    Note
    Documentation Required

    Required documentation checklist for PVI prior-authorization

    Submit prior-authorization for peripheral vascular intervention (PVI) requests with documentation showing the proposed procedure, condition treated, detailed prior conservative treatment and response, prior interventions and response, aneurysm location/size if present, nature of CLI (non-healing wound or ischemic rest pain), and recent (within 6 months) diagnostic imaging and clinical evaluation.

    • Include imaging reports (duplex, CTA/MRA/angiogram/IVUS) completed within 6 months and clinical notes documenting symptoms and exam (ulcer size/location if present).
    • Provide a clear description of prior conservative measures and objective response.
    Documentation Required

    Document method and percent of arterial stenosis (NASCET/duplex/CTA/MRA) correlated with symptoms

    Document the arterial stenosis measurement method and percent (angiogram, CTA, carotid duplex, or MRA) and correlate the imaging with symptoms or recurrent stenosis status (e.g., NASCET ≥70% for asymptomatic CEA within 6 months; ≥50% for symptomatic CEA).

    • State imaging modality and measurement method (NASCET when applicable) and include the percent stenosis.
    • Correlate imaging findings with clinical symptoms or recurrent restenosis thresholds (duplex PSV values for carotid restenosis).
    Documentation Required

    Document clinical history that meets procedure-specific criteria (e.g., CPT 34717 concurrent AAA and size requirements)

    Clinical history must explicitly document the criteria supporting the chosen procedure (e.g., planned simultaneous AAA repair when requesting CPT 34717; common iliac aneurysm >3.5 cm or internal iliac aneurysm ≥3.0 cm when applicable).

    • For CPT 34717 document concurrent AAA repair planning, ipsilateral common iliac aneurysm >3.5 cm, and contralateral IIA occlusion.
    • For isolated internal iliac aneurysm treatment document aneurysm ≥3.0 cm if asymptomatic or any symptomatic aneurysm or evidence of bleeding.
    Documentation Required

    Include diagnostic imaging documenting aneurysm size and symptom‑specific findings for aneurysm PA

    Provide diagnostic imaging (US, CT, MRI, CTA, MRA or angiogram) documenting aneurysm size and, for symptomatic popliteal aneurysms, include evidence of mural thrombus and new onset claudication, CLI, or blue toe syndrome to support authorization.

    • For popliteal aneurysm: imaging showing diameter ≥2.0 cm (asymptomatic) or ≥1.5 cm with mural thrombus plus ischemic symptoms (symptomatic pathway).
    • For visceral aneurysms include CTA/MRA/US/angiogram measurements meeting vessel-specific thresholds (e.g., hepatic ≥2.0 cm; splenic ≥3.0 cm or any size in child-bearing potential).
    Documentation Required

    Document condition‑specific findings for brachiocephalic PTA/stent authorization

    For brachiocephalic artery interventions include condition‑specific findings (e.g., symptomatic subclavian steal with episodic dizziness, advanced imaging showing high‑grade proximal subclavian stenosis, and duplex evidence of vertebral flow reversal) in the authorization submission.

    • Document symptoms, advanced imaging demonstrating high‑grade stenosis or occlusion, and duplex confirmation (e.g., vertebral flow reversal) when applicable.
    • Include objective evidence of ischemia or non-healing tissue when treating arm ischemia or ulcers.
    Documentation Required

    Required clinical documentation: symptom-location correlation and objective imaging (≥50% stenosis; PAT >225 ms when inframalleolar)

    Clinical notes must document symptoms consistent with lesion location, prior conservative therapy for claudication, and objective imaging confirming location and degree of stenosis (e.g., ≥50%); inframalleolar interventions require imaging showing lack of distal flow or PAT >225 ms.

    • Correlate symptoms to lesion location (aorto‑iliac vs superficial femoral vs popliteal) and provide imaging demonstrating ≥50% stenosis.
    • For inframalleolar cases include GLASS P2 descriptors, occluded distal vessels on CTA/MRA/angiogram or duplex showing lack of flow, or PAT >225 ms.
    Documentation Required

    Submit venous duplex within 6 months showing truncal reflux ≥500 ms and absence of ipsilateral DVT

    A venous duplex study completed within 6 months must be submitted showing required reflux measurements for saphenous/truncal veins (≥500 ms per segment rules) and absence of ipsilateral acute DVT or chronic multisegmental femoral‑popliteal occlusion.

    • Submit duplex completed within 6 months documenting ≥500 ms truncal reflux with the segment-specific requirements (e.g., ≥2 segments for above‑knee GSV).
    • Confirm absence of ipsilateral acute DVT or chronic multisegmental femoral‑popliteal occlusion.
    Documentation Required

    PA documentation for perforator treatment: duplex (≥500 ms, ≥3.5 mm), CEAP/VCSS, and saphenous status

    For perforator treatment near an active ulcer submit a recent venous duplex (within 6 months) documenting perforator reflux ≥500 ms AND vein diameter ≥3.5 mm, CEAP/VCSS to demonstrate symptom severity, and confirmation that saphenous veins draining the ulcer have been treated or are not pathologic.

    • Provide duplex demonstrating perforator incompetence (reflux ≥500 ms and diameter ≥3.5 mm) adjacent to the active ulcer.
    • Include CEAP or VCSS scores and documentation of prior saphenous vein treatment or absence of saphenous reflux.
    Documentation Required

    Require recent duplex (≤6 months) showing ≥500 ms reflux and CEAP/VCSS documentation for venous PA

    A venous duplex ultrasound within 6 months demonstrating required reflux criteria (≥500 ms in specified segments or diameter thresholds for perforators/tributaries) and clinical documentation of CEAP ≥ C2 or VCSS ≥6 are required for authorization of venous procedures.

    • Duplex recency must be within 6 months and show required reflux thresholds (≥500 ms) per vein/segment.
    • Include CEAP classification or VCSS to document symptom severity and relationship to venous disease.
    Documentation Required

    Document CEAP/VCSS, attributable symptoms, and qualifying imaging within 6 months for venous PA

    Providers must document clinical classification (CEAP C2+ or VCSS ≥6), symptoms attributable to venous disease, and imaging (venous duplex or other specified imaging) performed within 6 months showing required reflux, vein diameters, or stenosis measurements to support authorization.

    • CEAP C2+ or VCSS ≥6 should be recorded in the clinical documentation.
    • Include imaging within 6 months showing required physiologic and anatomic thresholds (reflux ≥500 ms; varicosity/tributary size thresholds; iliac/IVC stenosis thresholds where applicable).
    Documentation Required

    Provide imaging demonstrating required stenosis/diameter thresholds and correlate with clinical signs

    Imaging documentation (venogram, IVUS, CT/MR/ultrasound) demonstrating specified degrees of stenosis or vein diameters and clinical signs/symptoms relevant to the indication (e.g., arm edema, venous claudication, inadequate dialysis performance, lifestyle‑limiting SVC symptoms) is required to support medical necessity and authorization.

    • Use modality-appropriate measurements (IVUS/venography for area reduction or diameter stenosis; duplex/CTA/MRA for arterial stenosis percentages).
    • Correlate imaging findings with clinical manifestations (e.g., dialysis dysfunction, edema, ulceration, SVC symptoms).
    Documentation Required

    Submit CTA/MRA/US/angiogram documenting visceral aneurysm size to meet PA thresholds

    Diagnostic imaging (CTA, MRA, US, angiogram) is required to demonstrate visceral artery aneurysm or pseudoaneurysm and to measure size thresholds that meet coverage criteria (e.g., hepatic ≥2.0 cm, splenic ≥3.0 cm or any size in child‑bearing potential, renal ≥3.0 cm).

    • Include imaging modality and measured aneurysm diameter in the PA submission.
    • Document any symptomatic features or evidence of bleeding when present.
    Documentation Required

    Document primary clinical intent and separate anatomical fields for multi‑area procedures

    Document the primary clinical intent and anatomic treatment fields in the authorization request; when multiple anatomical areas are treated document them as separate operative fields to allow independent reporting.

    • State the dominant therapeutic intent for embolization coding selection (hemorrhage control, tumor ischemia, venous malformation, etc.).
    • When treating multiple distinct anatomical areas provide clear documentation distinguishing each operative field.
    Billing Rule

    Follow coding guidance: select correct embolization CPT (37241–37244) that matches documented intent

    Use the correct embolization CPT codes (37241–37244) per coding guidance in PA requests to avoid billing issues; ensure the code selected matches the documented primary intent and vessel type.

    • Refer to CPT guidance: 37241 for venous malformations/varices/varicoceles, 37242 for arterial non‑hemorrhage, 37243 for tumor/organ ischemia, 37244 for hemorrhage control.
    • Only one primary embolization code should be reported per treatment field.
    Denial Risk

    Insufficient documentation may lead to PA denial — include all required elements

    Prior-authorization requests lacking required documentation (procedure matching clinical need, condition, conservative treatment details, prior interventions, lesion location/size, nature of CLI, and recent diagnostic imaging/clinical evaluation) may be denied.

    • Insufficient documentation of imaging (within 6 months), clinical severity (e.g., CEAP/VCSS), or prior conservative therapy are common triggers for denial.
    • Ensure all items from the PVI PA documentation checklist are included to reduce denial risk.
    Denial Risk

    CEA/CAS exclusion: disabling stroke (modified Rankin ≥3) — risk of denial

    Carotid revascularization (CEA or CAS) is not medically necessary for individuals who have had a disabling stroke (modified Rankin scale ≥3); authorization requests for such cases risk denial unless life expectancy/benefit considerations are documented.

    • Document modified Rankin scale and life-expectancy/benefit rationale for asymptomatic individuals.
    • Requests for individuals with modified Rankin ≥3 are considered not medically necessary.
    Denial Risk

    Vertebral artery stenting beyond specified criteria considered experimental — denial risk

    Extracranial vertebral artery angioplasty with stent placement is considered experimental/investigational and unproven for indications other than the specified symptomatic criteria; authorization for non‑specified indications may be denied.

    • Authorization should be supported by documented symptomatic failure of medical therapy and meeting the specified vertebral stenosis criteria (60–99%) to avoid being considered investigational.
    • Asymptomatic vertebral stenosis requests are not supported by the guideline.
    Denial Risk

    Missing CPT‑specific criteria for CPT 34717 (iliac endograft) may cause denial

    Absence of documented CPT‑specific criteria (for example, planned concurrent AAA repair, ipsilateral common iliac aneurysm >3.5 cm, and contralateral IIA occlusion for CPT 34717) may trigger denial of requests for iliac endograft procedures.

    • For CPT 34717 include explicit documentation of concurrent AAA repair planning, aneurysm size (>3.5 cm), and contralateral IIA occlusion.
    • Lack of these elements may result in non-authorization.
    Denial Risk

    CPT 34718 (bifurcated‑bifurcated repair) is experimental — high denial risk

    CPT 34718 (bifurcated‑bifurcated aneurysm repair) is categorized as experimental, investigational, and unproven; authorization requests for CPT 34718 may be denied as not medically necessary.

    • Do not expect routine coverage for CPT 34718; provide strong evidence if requesting exceptional review.
    • Alternate supported approaches should be considered per guideline.
    Denial Risk

    Popliteal aneurysm PA denial risk if size/symptom criteria not met

    Requests for endovascular repair of popliteal aneurysms that do not meet size/symptom thresholds (asymptomatic <2.0 cm or symptomatic <1.5 cm without required mural thrombus and ischemic findings) may be denied.

    • Asymptomatic repair requires diameter ≥2.0 cm on imaging.
    • Symptomatic repair requires diameter ≥1.5 cm PLUS documentation of mural thrombus and ischemic sequelae (new claudication, CLI, or blue toe syndrome).
    Denial Risk

    Visceral aneurysm embolization denial risk if size/vessel criteria not met

    Coil embolization for visceral artery aneurysm/pseudoaneurysm that falls outside the listed vessel‑ and size‑specific indications (e.g., hepatic ≥2.0 cm; splenic ≥3.0 cm or any size if child‑bearing potential) may not meet medical necessity and risk denial.

    • Provide imaging showing aneurysm measurements meeting the guideline's vessel‑specific thresholds to support authorization.
    • Requests outside these thresholds should include compelling clinical justification to avoid denial.
    Denial Risk

    Staging without documented valid justification risks denial

    Staging of interventions without documented valid justification in the medical record (patient instability, excess fluoroscopy, unavailable anesthesia resources, or contrast >200 mL) may be denied as not medically necessary.

    • Document specific reason(s) for staging in the record to support authorization.
    • Absent justification, staged procedures are considered not medically necessary.
    Denial Risk

    Denial risk for non‑indicated infra‑popliteal/asymptomatic interventions (<50% stenosis)

    Intervention (PTA or stent) for asymptomatic individuals or for lesions that are not high‑grade/critical (<50%) and routine infrapopliteal/inframalleolar interventions for claudication are not considered medically necessary and are denial triggers.

    • Document symptomatic status and objective ≥50% stenosis for interventions; asymptomatic or <50% lesions generally do not meet criteria.
    • Routine below‑knee interventions for claudication lack evidence and are typically not authorized.
    Denial Risk

    Renal intervention denial risks when uncontrolled hypertension or transplant criteria not documented

    Renal artery interventions lack indication without uncontrolled hypertension; presence of advanced renal disease (hemodialysis) or chronic renal artery occlusion should be documented and may preclude authorization.

    • Intervention is indicated when medical therapy fails to control hypertension and imaging confirms renal artery stenosis.
    • Requests without uncontrolled hypertension or in hemodialysis patients are unlikely to meet medical necessity.
    Denial Risk

    Saphenous vein PA risk: missing qualifying duplex or CEAP/VCSS documentation

    Saphenous vein treatment requests missing a qualifying venous duplex within 6 months demonstrating pathologic truncal vein reflux (≥500 ms) or lacking symptom documentation (CEAP ≥ C2 or VCSS ≥6) risk non‑authorization.

    • Ensure duplex within 6 months with segment‑specific reflux documentation (≥500 ms) and CEAP/VCSS scoring are submitted with PA.
    • Absence of these items is a common cause for denial.
    Denial Risk

    Denial triggers for non‑compounded foam sclerotherapy: missing CEAP/VCSS or recent duplex; DVT/occlusion present

    Treatment requests for non‑compounded foam sclerotherapy lacking documentation of symptomatic reflux (CEAP ≥ C2 or VCSS ≥6) or a venous duplex within 6 months showing required reflux parameters, or with ipsilateral acute DVT or chronic multisegmental femoral‑popliteal occlusion, may be denied.

    • Include CEAP/VCSS and duplex showing ≥500 ms truncal reflux per segment requirements for 36465/36466 authorization.
    • Contraindications such as ipsilateral acute DVT or chronic multisegmental femoral‑popliteal occlusion should be identified and will preclude treatment.
    Denial Risk

    Missing recent qualifying duplex or presence of ipsilateral DVT/occlusion may cause denial

    Absence of documented qualifying venous duplex within 6 months showing required anatomic reflux (e.g., ≥500 ms in required segments) or presence of ipsilateral acute DVT or chronic multisegmental femoral‑popliteal occlusion may trigger denial for venous procedures.

    • Ensure duplex studies are recent (≤6 months) and show the exact reflux measurements and segment counts required by the criteria.
    • Active ipsilateral DVT or chronic multisegmental occlusion are contraindications and should be documented if present.
    Denial Risk

    Denial risk if recent duplex and CEAP/VCSS not provided for venous PA

    Lack of a recent (within 6 months) venous duplex demonstrating required reflux measurements (e.g., ≥500 ms) or absence of required clinical classification (CEAP C2+ or VCSS ≥6) may result in denial for venous interventions.

    • Venous duplex recency and CEAP/VCSS are essential elements for authorization of saphenous/truncal vein and sclerotherapy procedures.
    • Submit both imaging and clinical severity documentation to reduce likelihood of denial.
    Denial Risk

    Iliac/IVC stenting requires imaging documenting ≥50% area reduction or >60% diameter stenosis — omission risks denial

    Iliac/IVC stenting without documentation of ≥50% area reduction or >60% diameter stenosis (or without required associated clinical findings or failed 8‑week conservative therapy) may trigger denial.

    • Provide IVUS/venogram/CT/MR demonstrating ≥50% area reduction or >60% diameter stenosis and correlate with clinical sequelae (ulceration, advanced stasis dermatitis, venous claudication, asymmetric edema).
    • Document failed 8‑week conservative therapy unless urgent indication exists.
    Denial Risk

    Left renal vein stenting for primary nutcracker treatment is NMN — denial risk

    Angioplasty or stenting of the left renal vein for primary treatment of nutcracker syndrome is considered not medically necessary; requests for primary endovascular treatment prior to surgical decompression are usually denied.

    • Primary endovascular treatment of left renal vein compression (nutcracker) prior to surgical decompression is NMN.
    • Authorization for re‑intervention after prior surgical decompression may be considered when recurrent imaging‑documented compression and symptoms are present.
    Denial Risk

    Prophylactic aortic side branch embolization prior to EVAR is not indicated — denial risk

    Embolization of aortic side branches prior to EVAR solely to prevent Type 2 endoleak is not medically necessary; requests for prophylactic embolization for EVAR may be denied.

    • Do not submit authorization requests for embolization of lumbar or inferior mesenteric branches purely to prevent Type 2 endoleak.
    • If embolization is performed for therapeutic bleeding or other supported indication, include that documentation.
    Denial Risk

    Embolization for non‑listed indications is NMN — expect denial without strong justification

    Requests for embolization for indications not listed in this guideline are considered not medically necessary and may be denied; provide evidence‑based justification if pursuing an unlisted indication.

    • Embolization is covered for listed organ‑ and condition‑specific indications; unlisted uses lack guideline support.
    • Include literature or multisociety guidance only when requesting exceptional consideration for non‑listed indications.
    Billing Rule

    Coding accuracy for embolization (37241–37244) required — incorrect coding risks audit/denial

    Incorrect embolization coding (mismatching CPT 37241–37244 to the documented primary intent or vessel type) may trigger audit or denial; ensure coding aligns with the documented clinical intent and operative field.

    • Select only one primary embolization code per treatment field based on the dominant therapeutic intent.
    • Document vessel type and primary intent clearly in the PA to support selected CPT code(s).
    Imaging confirming >=50% stenosis by objective criteria supports CLI interventions.
    inv-201: Aneurysm
    Aneurysm size-based thresholdsVisceral and aortoiliac aneurysm interventions use vessel-specific size thresholds (eg, common iliac >3.5 cm, internal iliac >=3.0 cm, hepatic >=2.0 cm, splenic >=3.0 cm).
    Symptomatic vs asymptomaticSymptomatic aneurysms of any size or evidence of bleeding support intervention regardless of size for some vessels (eg, internal iliac, splenic PSA).
    inv-202: Carotid endarterectomy (CEA)
    CEA indications summaryCarotid endarterectomy (CEA) is preferred for symptomatic carotid stenosis >=50% and for asymptomatic stenosis >=70% (NASCET) when documented within 6 months.
    CAS/TCAR roleCAS or TCAR considered when patient meets revascularization criteria but is high-risk for CEA; CAS typically performed with embolic protection; TCAR uses flow reversal.
    inv-203: Carotid angioplasty and stenting (CAS)
    CAS indicationsConsidered medically necessary when individual meets carotid revascularization criteria and is high-risk for CEA (list of comorbidities/anatomic factors provided).
    Embolic protection and facility competencyCAS is typically performed with embolic protection; CMS competency expectations require facilities to be competent in evaluation, procedure, and follow-up.
    inv-204: Transcarotid artery revascularization (TCAR)
    TCAR descriptionTranscarotid artery revascularization (TCAR) deploys a transcarotid stent under reverse carotid flow (flow reversal) to reduce cerebral embolization and is used in high-risk patients.
    IndicationTCAR is an option for individuals considered high-risk for CEA and meeting revascularization criteria.
    inv-205: Aortoiliac pathology
    Aortoiliac pathology scopeIncludes aneurysm formation (including pseudoaneurysm), aortic dissection (acute/chronic), penetrating aortic ulcer, and atherosclerotic occlusive disease.
    Procedural coding contextIliac branched endograft deployment (CPT 34717) is described in detail for endovascular repair concurrent with AAA endograft placement.
    inv-206: Iliac branched endograft repair (CPT 34717, 34718)
    Iliac branched endograft codesCPT 34717 (endograft concurrent with aorto-iliac endograft) and CPT 34718 (isolated iliac branched endograft) are referenced; 34717 has explicit size/contra-lateral occlusion criteria.
    Clinical criteria for 34717Ipsilateral common iliac aneurysm >3.5 cm, planned concurrent AAA repair, and contralateral IIA occlusion required for medical necessity.
    inv-207: Popliteal artery aneurysm
    Popliteal artery aneurysm definitionPopliteal artery aneurysm defined as diameter >1.5 cm or 1.5× normal (normal 5–9 mm); most are asymptomatic but can lead to embolization/thrombosis.
    Repair thresholdsAsymptomatic >=2.0 cm; symptomatic >=1.5 cm with mural thrombus plus ischemic symptoms.
    inv-208: Revascularization, endovascular/open/percutaneous
    Revascularization general useRevascularization procedures (endovascular, open, percutaneous) are indicated when imaging confirms anatomic lesion and clinical criteria such as claudication or CLI are met; imaging thresholds generally >=50% stenosis.
    Lesion descriptors'Straightforward' denotes a stenosis; 'Complex' denotes an occlusion on preoperative imaging.
    inv-209: Intravascular lithotripsy HCPCS
    Intravascular lithotripsy HCPCS rangeHCPCS C9764–C9775 describe intravascular lithotripsy procedures for lower extremity arteries.
    Indication contextIVL coverage tied to evidence of moderate/severe calcified plaque and CLI/lesion-specific criteria.
    inv-210: Straightforward lesion
    Straightforward lesion definitionLesions identified on preoperative imaging as a stenosis.
    ImplicationUsed to select appropriate CPT codes and procedural planning (eg, atherectomy vs PTA).
    inv-211: Complex lesion
    Complex lesion definitionLesions identified on preoperative imaging as an occlusion.
    ImplicationMay influence selection of codes, expected complexity, and necessity of adjunctive techniques.
    inv-212: GLASS inframalleolar classification (P0–P2)
    GLASS inframalleolar classification (P0–P2)P0–P2 denote target artery crossing the ankle and pedal arch status; P2 indicates no target artery crossing the ankle into the foot and supports inframalleolar intervention when active tissue loss is present.
    Use caseGLASS P2 descriptor is used as part of imaging criteria for inframalleolar angioplasty decisions.
    inv-213: Inframalleolar/pedal intervention
    Inframalleolar/pedal intervention stanceInterventions below the malleolus are limited to individuals with active ulcers or tissue loss; not indicated for rest pain or claudication due to limited durability evidence.
    Imaging supportCTA/MRA/angiogram or duplex demonstrating occluded distal ATA/DP or PTA/Tarsal branches, lack of flow, or PAT >225 ms required.
    inv-214: Significant truncal vein reflux
    Significant truncal vein refluxVenous duplex reflux measuring >=500 ms in specified vein segments (segment-specific minima apply) is an objective criterion for saphenous vein treatment.
    ApplicationRequired for endovenous ablation, sclerotherapy, high ligation/stripping, and related procedures when CEAP C2+ or VCSS >=6 and duplex within 6 months are present.
    inv-215: Pathologic truncal vein reflux
    Pathologic truncal vein reflux definitionReverse flow on duplex ultrasound lasting >=500 ms in affected vein segments.
    Segment rulesSome veins require reflux in >=2 segments (eg, GSV above-knee) while others require >=1 segment (eg, ASV, GSV below-knee).
    inv-216: Pathologic perforator (for ulcer treatment)
    Pathologic perforator (ulcer treatment)Perforator vein adjacent to active venous stasis ulcer with duplex demonstrating reflux >=500 ms and diameter >=3.5 mm.
    Treatment limitationPerforator treatment is indicated only for active ulceration and after saphenous veins draining the ulcer have been eliminated or are non-refluxing.
    inv-217: Pathologic perforator (duplicate)
    Pathologic perforator (general)A perforator demonstrating reflux >=500 ms and meeting diameter criteria, particularly when located adjacent to an active venous stasis ulcer; treatment limited to ulcer cases.
    Contraindication noteTreatment of pathologic perforators for indications other than active venous stasis ulcer is not medically necessary.
    inv-218: Significant pathologic truncal reflux (duplicate)
    Significant pathologic truncal reflux (restated)Reflux measuring >=500 ms in specified vein segments; criteria differ by vein — some require >=2 segments for certain trunks.
    Clinical implicationThreshold used to determine eligibility for truncal vein ablation and sclerotherapy when symptomatic (CEAP C2+ or VCSS >=6).
    inv-219: Pathologic truncal vein reflux (duplicate)
    Pathologic truncal vein reflux (duplicate)Reflux >=500 ms on venous duplex in specified truncal vein segments (segmentation rules apply).
    DocumentationVenous duplex must be within 6 months and show the required reflux measurements.
    inv-220: Pathologic perforator (duplicate)
    Pathologic perforator (duplicate)Perforator vein with reflux >=500 ms and diameter >=3.5 mm located near an active venous stasis ulcer qualifies for intervention.
    Sequence requirementSaphenous treatment should be performed prior to perforator intervention when relevant.
    inv-221: Venous thoracic outlet syndrome (TOS)
    Venous TOS definitionCompression of the axillo-subclavian vein from musculoskeletal structures (eg, cervical rib, scalene hypertrophy) causing thrombosis or chronic edema; management includes DVT care and surgical decompression.
    Stenting noteStenting is rarely necessary except for persistent stenosis resistant to angioplasty.
    inv-222: Pelvic congestion syndrome (PCS)
    Pelvic congestion syndrome imaging criteria (ultrasound)Tortuous pelvic veins diameter >6 mm, slow flow <3 cm/sec or reversed caudal flow support PCS.
    CT/MR criteriaFour ipsilateral tortuous para-uterine veins >4 mm or ovarian vein diameter >8 mm on CT/MR support PCS.
    inv-223: Arteriovenous malformation embolization
    AVM embolization indicationsEmbolization/occlusion is medically necessary prior to planned surgery/SRS or when lesion affects a vital structure, causes bleeding, high-output heart failure, pain, infection, or impairs activities of daily living.
    DocumentationDiagnostic imaging and clinical history must support the primary intent for embolization.
    inv-224: Visceral artery aneurysm thresholds
    Visceral aneurysm thresholds (recap)Hepatic >=2.0 cm; celiac >=2.0 cm (or any celiac PSA); jejunal/ileal >=2.0 cm; SMA and others any size per vessel-specific rules; splenic >=3.0 cm or any size if child-bearing potential; renal >=3.0 cm.
    Imaging requirementCTA, MRA, US, or angiogram required to measure size and document indication prior to coil embolization.
    inv-225: Primary clinical intent
    Primary clinical intentThe dominant reason for the intervention (eg, hemorrhage control, tumor ischemia, variceal treatment) determines embolization code selection; code one primary service per treatment field.
    Coding guidanceWhen multiple distinct anatomical areas are treated, each area may be reported independently with clear documentation distinguishing operative fields.
    inv-226: Pelvic congestion syndrome imaging criteria
    PCS ultrasound criterionTortuous pelvic veins >6 mm on ultrasound supports pelvic congestion syndrome and embolization.
    Clinical contextChronic pelvic pain >6 months with characteristic symptoms and absence of inflammatory disease required.
    inv-227: Pelvic venous disorders (PeVD) V3a
    PeVD V3a inclusionPelvic venous disorders V3a includes extra-pelvic varices (eg, varicocele, vulvar varices) originating from pelvic veins; pelvic vein embolization is supported for V3a varices.
    Evidence noteAVLS working group report (Meissner et al., 2021) supports pelvic vein embolization for V3a varices.